NZ202907A - 4-cyano-2-azetidinone derivatives;pharmaceutical compositions containing them and their use in preparing 4-carbamoyl-2-azetidinones - Google Patents

4-cyano-2-azetidinone derivatives;pharmaceutical compositions containing them and their use in preparing 4-carbamoyl-2-azetidinones

Info

Publication number
NZ202907A
NZ202907A NZ202907A NZ20290782A NZ202907A NZ 202907 A NZ202907 A NZ 202907A NZ 202907 A NZ202907 A NZ 202907A NZ 20290782 A NZ20290782 A NZ 20290782A NZ 202907 A NZ202907 A NZ 202907A
Authority
NZ
New Zealand
Prior art keywords
group
compound
formula
amino
cyano
Prior art date
Application number
NZ202907A
Inventor
M Ochiai
T Matsuo
S Kishimoto
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NZ202907A publication Critical patent/NZ202907A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

New Zealand Paient Spedficaiion for Paient Number £02907 2 02907 PATENTS ACT 1953 COMPLETE SPECIFICATION 4-Cyano-2-Azetidinones and Production thereof" -L,WE TAKEDA CHEMICAL INDUSTRIES, LTD. 27 Doshomachi 2-chome, Higashi-ku, Osaka 541 Japan, a Japanese company, hereby declare the invention, for which-f/we pray that a patent may be granted to-ree-/us, and the method by which it is to be performed, to be particularly described in and by the following statement (followed by page I A.) - lA- 2 02907! SPECIFICATION 4-Cyano-2-Azetidinones and Production Thereof Technical Field This invention relates to a new class of 4-cyano-2-azetidinone derivatives which are useful for the synthesis of optically active forms of 4-substituted-2-azetidinone derivatives and some of which have antimicrobial and 3<-lactamase-inhibitory activity, a method of producing said class of derivatives, and a method of using them as synthetic intermediates.
Background Technology Recently, a new class of g-lactam antibiotic compounds having a sulfo group in 1-position have been found to be recoverable from nature sources and reported [Nature 2 89, 590 (1981), 291, 489 (1981)]. Synthesis of compounds related thereto has also been reported (e.g. EP*-A1-0021678 and EP-A1-0048953) . The latter literature teaches a method of synthesizing 2-azetidinone-l-sulfonic acid compounds having a substituent in 4-position but the method involves a long series of reaction steps and no expedient process for the purpose has been reported.
Disclosure of the Invention This invention relates to a novel class of 4-cyano-2-azetidinone derivatives having the formula: r1 x cn \/ / .i [I] 0^ w [R^" is an amino group which may optionally be acylated or protected; X is H or methoxy; W is H or sulfo], *- { f'M ' a method for producing said derivatives [I] and a method of using them [I] as synthetic intermediates.
The research undertaken by the present inventors led - 2 - 202907 to the finding that if a compound of the formula: R2 X y \Z NH O 2 [R is an acylated or protected amino group; Y is halogen or a group of the formula Q g "3 "3 3 3 -O-C-R , -O-C-R or -S-R (R is I (0)n hydrocarbyl; n is an intefer of 1 or 2); X has the meanings defined above] is reacted with a cyano compound and thus obtained compound [I] wherein W is H may optionally be further sulfonated to obtain compound [I] wherein W is sulfo, and, if necessary, the amino-protecting group is eliminated, there is obtained a 4-cyano-2-azetidinone derivative [I] and that this derivative [I] is useful as an intermediate for the synthesis of 4-substituted-2-azetidinone derivatives and particularly of optically active forms thereof. To elaborate on the latter finding, it was found that if the compound [I] is hydrated and, if necessary, the amino-protecting group is eliminated, there is obtained a 4-carbamoyl-2-azetidinone derivative of the formula: [III] 4 [R is an acylated or protected amino group; X has the meanings defined above].
This invention has been conceived and developed on the basis of the above findings. 2 02907 Referring to the above formulas, the acyl moiety of 12 4 tne acylated amino group R , R , R may for example be one of those acyl groups substituting the 6-amino groups of the known penicillin derivatives or the 7<-amino groups of the known cephalosporin derivatives. Specific examples of such acyl groups include, among others, (1) groups of the formula: R5-C0- [A] [R is lower alkyl, optionally substituted phenyl or optionally substituted heterocyclic group], (2) groups of the formula: R -NH-CH-CO- [B] R7 [R^ is H, optionally substituted amino acid residue, amino- g protecting group or a group of the formula R -(CH2)m-C0-(R^ is amino, optionally substituted heterocyclic group, optionally substituted phenyl or optionally substituted 7 lower alkyl; m is an integer of 0 to 3); R is H, optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted heterocyclic group or optionally substituted cycloalkenyl]; (3) groups of the formula: [R^ is a group of the formula R-L-'-C- (rH is optionally II 12 N-O-R substituted heterocyclic group or optionally substituted 9 in R -R -CO- [C] 202907 phenyl; R12 is H, optionally substituted phenyl, C2_4 acyl, lower alkyl or a group of the formula -R*3-R14 (R13 is C1_3 14 •c • j alkylene or C2_3 alkenylene; R is carboxy or esterifled carboxy); R10 is a bond or a group of the formula -CO-NH-CH- I15 (R15 is lower alkyl or optionally substituted heterocyclic group)]; (4) groups of the formula: R17 L (/ N\- CH-CO- [D] if* [R"^ is hydroxy, carboxy, sulfo, formyloxy, halo or azido; 17 .
R is h, lower alkyl, alkoxy, halo or hydroxy]; and (5) groups of the formula: r18-r19-ch2-co- [e] 18 [R is cyano, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted lower alkyl, optionally substituted alkenyl or optionally substituted 19 heterocyclic group; R is a bond or -S-].
In the above groups, the group is preferably a group of O I the formula: R -conh-ch-co- J 7 1 8 1 wherein R and R are a heterocyclic group which may be substituted, and the group (c) is preferably a group of the 11 • formula: R -C-CO- II N J 12- OR wherein R^"*" is a heterocyclic group which may be substituted, 12 ' u and R is a lower alkyl group. ^ k V , 202907 19 Referring to R through R in the above formulas [A] through [E], the lower alkyl group is a group of 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, etc.
The C^_g alkoxy includes C^_g alkoxy groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, hexyloxy, and isohexyloxy. The alkenyl includes vinyl, allyl, isopropenyl, 2-methallyl, 2-butenyl and 3-butenyl.
The cyclo-alkenyl is preferably of the 5- or 6-membered ring, for example, cyclohexenyl and cyclohexadienyl.
The lower alkylene preferably contains 1-3 carbon atoms and is, for example, methylene, dimethylene, ethylene, methylethylene or trimethylene. The lower alkenylene preferably contains 20Z90T b g-3 carbon atoms and is, for example, vinylene or propenylene Examples of the halogen are chlorine, bromine, iodine, and fluorine.
The heterocyclic group includes, among others, 5- to 8-membered rings containing 1 to a few hetero atoms such as N (which may form an oxide), 0 and S, as well as fused ring structures involving such rings, which are bonded through a carbon atom thereof. Thus, for example, frequently used are such heterocyclic groups as 2- or 3-pyrrolyl, 2-or 3-furyl, 2- or 3-thienyl, 2- or 3-pyrrolidinyl, 2-, 3-or 4-pyridyl, N-oxido-2-, 3- or 4-pyridyl, 2-f 3- or 4-piperidinyl, 2-, 3- or 4-pyranyl, 2-, 3- or 4-thiopyranyl, pyrazinyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isothiazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or -imidazolyl, imidazolidinyl, 3-, 4- or 5-pyrazolyl, pyrazolidinyl, 3- or 4-pyridazinyl, N-oxido-3- or 4-pyridazinyl, 2-, 4- or 5-pyrimidinyl, N-oxido-2-, 4- or 5-pyrimidinyl, piperazinyl, 4- or 5-(1,2,3-thiadiazolyl), 3-or 5-(1,2,4-thiadiazolyl), 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 4- or 5-(1,2,3-oxadiazolyl), 3- or 5-(1,2,4-oxadiazolyl), 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-or 1,2,4-triazolyl, 1H- or 2H-tetrazolyl, pyrido(2,3-d)-pyrimidyl, benzopyranyl, 1,8-, 1,5-, 1,6-, 1,7-, 2,7- or 2,6-naphthyridyl, quinolyl, thieno(2,3-b)pyridyl, etc. The amino acid residue includes glycyl, alanyl, valyl, leucyl, isoleucyl, seryl, threonyl, cysteinyl, cystyl, methionyl, a- or g-aspartyl, a- or 3-glutamyl, lysyl, arginyl, phenylalanyl, phenylglycyl, tyrosyl, histidyl, tryptophyl, and prolyl. The amino-protecting group includes those to be mentioned hereinbelow. The lower acyl preferably contains 2-4 carbon atoms and is, for example, acetyl, propionyl, butyryl, or isobutyryl. The substituent for the optionally substituted lower alkyl and for the optionally substituted alkenyl includes phenyl, carbamoyl, methylcarbamoyl, carboxy, cyano, halogen, hydroxy, etc. The substituents for the optionally substituted phenyl, -333E?'. phenoxy and cycloalkenyl include ^ lower alkyl, 3 lower alkoxy, halogen, amino, benzyloxy, hydroxy, C2 acyloxy, aminomethyl, carbamoylaminomethyl, 3-amino-3-carboxypropoxy, etc. The substituent for the optionally substituted heterocyclic group includes optionally substituted C^_g alkyl, lower alkoxy, hydroxy, carboxy, oxo, monochloroacetamido, aldehyde, trifluoromethyl, amino, halogen, optionally substituted phenyl such as mentioned above (e.g. 2,6-dichlorophenyl), coumarin-3-carbonyl, 4-formyl-l-piperazinyl, pyrrolealdoimino, furan-aldoimino, thiophenealdoimino, mesyl, mesylamino, amino-protecting groups, optionally halo-substituted ^ acyl-amino, etc. The amino-protecting groups include those to be mentioned hereinbelow. The optionally substituted amino acid residue includes amino, amino-protecting groups, carbamoyl, methylcarbamoyl, and benzyl. The amino-protecting groups include those to be mentioned hereinbelow. The 14 esterxfied carboxy group R includes methyl ester, ethyl ester, propyl ester, t-butyl ester, p-nitrobenzyl ester and 2-trimethylsilylethyl ester.
Amino, carboxy or/and hydroxy groups, if any, in 19 the above-mentioned substituents R through R may be protected. The amino-protecting groups in such cases may for example be "the amino-protecting groups" mentioned hereinafter for r\ The carboxy-protecting groups may be any and all groups which are commonly used for the protection of carboxy functions in 3-lactam or organic chemistry. Thus, for example, methyl, ethyl, n-propyl, isopropyl, tert-butyl, tert-amyl, benzyl, p-nitrobenzyl, p-methoxy-benzyl, benzhydryl, phenacyl, phenyl, p-nitrophenyl, methoxymethyl, ethoxymethyl, benzyloxymethyl, acetoxymethyl, pivaloyloxymethyl, 3-methylsulfonylethyl, methylthiomethyl, trityl, 3,3#B-trichloroethyl, 3-iodoethyl, 2-trimethylsilylethyl, trimethylsilyl, dimethylsilyl, acetylmethyl, -nitrobenzoylmethyl, p-mesylbenzoylmethyl, phthalimido-ethyl, propionyloxymethyl, mesylmethyl, benzenesulfonyl- 202307 <b - X - methyl, phenylthiomethyl, ester residues (e.g. dimethyl-aminoethyl) and silyl are used. Especially preferred are 3,3,3-trichloroethyl, p-nitrobenzyl, tert-butyl, 2-tri-methylsilylethyl and p-methoxybenzyl. The hydroxy-protect-ing group may be any and all groups which are commonly employed for the protection of hydroxy functions in 3-lactam or organic chemistry. Thus, for example, there may be mentioned ester residues such as acetyl, chloroacetyl, etc., esterified carboxy groups such as 3,3,3-trichloro-ethoxycarbonyl, 2-trimethylsilylethoxycarbonyl, etc., ether residues such as tert-butyl, benzyl, p-nitrobenzyl, trityl, methylthiomethyl, 3-methoxyethoxymethyl, etc., silyl ether residues such as trimethylsilyl, tert-butyldimethyl-silyl, etc., acetal residues such as 2-tetrahydropyranyl, 4-methoxy-4-tetrahydropyranyl, etc. These protective groups may be selected more or less liberally as it is true with amino- and carboxy-protecting groups.
Referring to the acyl groups mentioned earlier, the acyl group R -CO-[A] may for example be 3-(2,6-dichloro-phenyl)-5-methylisooxazol-4-yl-carbonyl. o 02907 -A Among specific examples of the acyl group R -NH-CH-CO- [B] k7 are D-alanyl, D-phenylalanyl, a-benzyl-N-carbobenzoxy-Y-D-glutamyl-D-alanyl, D-phenylglycyl-D-alanyl, N-carbobenzoxy-D-phenylglycyl, D-alanyl-D-phenylglycyl, Y-D-glutamyl-D-alanyl, N-carbobenzoxy-D-alanyl-D-phenylglycyl, D-carbamoyl-tryptophyl-D-phenylglycyl, N-[2-amino-3-(N-methylcarbamoyl) -propionyl]-D-phenylglycyl, N-carbobenzoxy-D-phenylglycyl-D-phenylglycyl, D-alanyl-D-alanyl, 2-[2-amino-3-(N-methylcarbamoyl )propionamido]acetyl, D-2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido) -2-(4-methoxyphenyl)acetyl, D-2-[2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido)acetamido]-2-phenylacetyl, 2-(2-aminothiazol-4-yl)-2-(4-ethyl-2,3-dioxo- 1-piperazinecarboxamido)acetyl, D-2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido)-2-thienylacetyl, D-2-(4-n-dodecyl-2,3-dioxo-l-piperazinecarboxamido)-2-phenylacetyl, D-2-(4 ,6t-diethyl-2,3-dioxo-l-piperazinecarboxamido) -2-phenyl-acetyl, D-2-(4-cyclohexyl-2,3-dioxo-l-piperazinecarboxamido)- 2-thienylacetyl, D-2-(4-n-amyl-6(S)-methyl-2, D-3-dioxo-l-piperazinecarboxamido)-2-thienylacetyl, D-2-(4-ethyl-5-methyl-2,3-dioxo-l-piperazinecarboxamido)-2-thienylacetyl, D-2-(8-hydroxy-l,5-naphthyridine-7-carboxamido)-2-phenyl-acetyl, D-2-(4-n-octyl-2,3-dioxo-l-piperazinecarboxamido)-2-phenylacetyl, 2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido)-2- (4-chlorophenyl) acetyl, cx-n- (4 -ethyl-2 ,3-dioxo-l-piperazine-carbonyl)glutaminyl, D-n-(4-ethyl-2,3-dioxo-l-piperazine-carbonyl)phenylalanyl, D-2-(4-ethyl-2,3-dioxo-l-piperaziJie-carboxamido)-2-(4-hydroxyphenyl)acetyl, 2-(4-ethyl-2,3- 15JUL1985m^ dioxo-l-piperazinecarboxamido)-2-(1-cylohexen-l-yl)acetyl, D-2-(4-n-octyl-2,3-dioxo-l-piperazinecarboxamido)-2-thienylacetyl , 2- (4-ethyl-2,3-dioxo-l-piperazinecarboxamido)-2-(2-methylthiazol-4-yl)acetyl, 2-(4-n-octyl-2,3-dioxo-l-piperazinecarboxamido)-2-(2-aminothiazol-4-yl)acetyl, 2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido)-2-furylacetyl, D-2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido)-2-(2-pyrrolyl)acetyl, D-2-(4-ethyl-2,3-dioxo-l-piperazine- 2.02907 /<? carboxamido)-3-chloropropionyl, D-2-[4-(2-hydroxyethyl)-2,3-dioxo-l-piperazinecarboxamido]-2-phenylacetyl, D-2-[4- (2-chloroethyl)-2,3-dioxo-l-piperazinecarboxamido]-2-phenylacetyl , D-2-[(3-furfurylideneamino-2-oxoiirtidazolidin-l-yl)carboxamido]-2-phenylacetyl, D-2-[(3-furfurylideneamino-2-oxoimidazolidin-l-yl)carboxamido]-2-(4-hydroxyphenyl)-acetyl, D-2-[[2-oxo-3-(thiophene-2-aldoimino)imidazolidin-1-yl]carboxamido]-2-phenylacetyl, D-2-[(3-furfurylideneamino-2-oxoimidazolidin-l-yl)carboxamido]-2-thienylacetyl, D-2-[(3-methylsulfonyl-2-oxoimidazolidin-l-yl)carboxamido]-2-phenylacetyl, 2-[(3-furfurylideneamino-2-oxoimidazolidin-l-yl)carboxamido]-2-(2-aminothiazol-4-yl)acetyl, D-2-[[2-oxo-3-(thiophene-2-aldoimino)imidazolidin-l-yl]carboxamido-2-thienylacetyl, D-2-(4-hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetyl, D-2-[5,8-dihydro-2-(4-formyl-l-piperazinyl)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamido]-2-phenylacetyl, D-2-(3,5-dioxo-l,2,4-triazine-6-carboxamido)-2-(4-hydroxyphenyl)acetyl, D-2-(coumarin-3-carboxamido)-2-phenylacetyl, 2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido)-2- (2-chloro-l-cyclohexen-l-yl)acetyl, 2-(4-hydroxy-7-trifluoromethylguinoline-3-carboxamido)-2-phenylacetyl, N-[2-(2-aminothiazol-4-yl)acetyl]-D-phenylglycyl, D-2-[ [3- (2 ,6-dichlorophenyl)-5-methylisoxazol-4-yl]carboxamido]-2-thienylacetyl, D-2-(carbamoyl)amino-2-thienylacetyl and N-carbamoyl-D-phenylglycyl. Among specific examples of the 9 10 acyl group R -R -CO- [C] are N-[2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl]-D-alanyl, 2-(2-chloroacetamidothiazol-4-yl)-2-methoxyiminoacetyl, 2-(2-aminothiazol-4-yl)-2-iso-propoxyiminoacetyl, 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl, 2-(2-aminothiazol-4-yl)-2-oxyiminoacetyl, 2-thienyl-2-methoxyiminoacetyl, 2-furyl-2-methoxyiminoacetyl, 2-(4-hydroxyphenyl)-2-methoxyiminoacetyl, 2-phenyl-2-methoxy-iminoacetyl, 2-thienyl-2-oxyiminoacetyl, 2-thienyl-2-aichloroacetyloxyiminoacety1, 2-[4-(3-amino-3-carboxy-propoxy)phenyl]-2-oxyiminoacetyl, 2-(5-chloro-2-amino-thiazol-4-yl)-2-methoxyiminoacetyl, 2-(2-aminothiazol-4- 202907 ii y> yl)-2-(1-carboxymethoxyimino)acetyl, 2-(2-aminothiazol-4-yl)-2-(1-carboxyethoxyimino)acetyl, 2-(2-aminothiazol-4-yl)-2-(1-carboxy-l-methylethoxyimino)acetyl, 2-(2-amino-thiazol-4-yl)-2-(1-methoxycarbonyl-l-methylethoxyimino)-acetyl, 2-(2-aminothiazol-4-yl)-2-(1-carboxy-l-cyclopropyl-methoxyimino)acetyl, 2-(2-aminothiazol-4-yl)-2-(1-carboxy- 1-cyclobutylmethoxyimino)acetyl and 2-(2-aminothiazol-4-yl)- 2-(1-carbamoyl-l-methylethoxyimino)acetyl. Among specific examples of the acyl group of the formula R17 A-cn-a CO- ( 1J) R16 are a-sulfophenylacetyl, a-hydroxyphenylacetyl, a-formyl- oxyphenylacetyl, a-carboxyphenylacetyl, 2-boro-2-phenyl- acetyl and 2-azido-2-phenylacetyl. Specific examples of the 18 19 acyl group of the formula R -R -CI^-CO- [E] are cyano-acetyl, phenylacetyl, phenoxyacetyl, trifluoromethylthio-acetyl, cyanomethylthioacetyl, lH-tetrazolyl-l-acetyl, 2-thienylacetyl, 2-(2-aminothiazol-4-yl)acetyl, 2-(2-chloro-acetamidothiazol-4-yl)acetyl, 4-pyridylthioacetyl, 3,5-dichloro-1,4-dihydro-4-oxopyridine-l-acetyl, g-carboxy-vinylthioacetyl, 2-(2-N-carbobenzoxyaminomethylphenyl)-acetyl and 2-(2-ureidomethylphenyl)acetyl.
As the protective groups in the protected amino groups 12 4 R , R and R , there may conveniently be used any of those commonly used for the same purpose in the field of beta-lactam chemistry and peptide synthesis. Thus, for example, aromatic acyl groups such as phthaloyl, p-nitrobenzoyl, p-tert-butyl-benzoyl, p-tert-butylbenzenesulfonyl, benzenesulfonyl and toluenesulfonyl, aliphatic acyl groups such as formyl, acetyl, propionyl, monochloroacetyl, dichloroacetyl, tri-chloroacetyl, methanesulfonyl, ethanesulfonyl, trifluoroacetyl, phenylacetyl, maloyl and succinyl, esterified carboxyl groups as benzyloxycarbony1,. p-nitrobenzyloxycarbonyl, p-methoxyl 2Q2907 - yC - carbonyl, 2-trimethylsilylethoxycarbonyl and methoxy-carbonyl, and other amino-protecting groups than acyl groups, such as trityl, 2-nitrophenylthio, benzylidene, 4-nitrobenzylidene, di- or trialkylsilyl, tert-butyldimethyl-silyl, tert-butyldiphenylsilyl, benzyl and p-nitrobenzyl may be employed. ) 502907 12, - yi - While these protective groups iray be selected liberally as it is true with carboxy-protecting groups, there iray be mentioned rronochloroacetyl, trityl, benzyloxycarbonyl, p-methoxy- benzyloxycarbonyl, 2-triirethylsilylethoxycarbonyl and p- nitrobenzyloxycarbonyl as preferred species. 0 Y ^presents a halogen atorr or a group of the forrrula -O-C-R3, -o-c-R3 or -S(0)n~R^ (R^ is hydrocarbyl; n is equal %t> 1 or 2). The halogen mentioned above is chlorine, fluorine, iodine or broirine. The hydrocarbyl group includes, airong others, such optionally substituted lower alkyl, alkenyl ana 19 cycloalkenyl groups as mentioned for R through R , cyclo-alkyl groups containing 3 to 10 carbon atoms such as cyclo-propyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adarrantyl, etc., aryl groups such as phenyl, tolyi, xylyl, biphenylyl, naphthyl, anthryl, phenanthryl, etc., and aralkyl ^fbups s^uch as. be*, etc. These cycloalkyl, arvl ana aralkyl groups may be substituted, in which cases the substituents tray be similar to those phenyl- or phenoxy-substituting groups mentioned for 5 19 R through R . Particularly satisfactory results are obtained when Y is for example a lover acvloxy (e.g. acetoxv, propionyl-oxy) or lower alkylsulfonyl (e.g. methylsulfonyl, ethvlsulfonyl) group. X is H or methoxy, and W is H or sulfo.
In accordance with this invention, a compound [II] is reacted with a cyano corrpound and, if necessary, the protective group is eliminated to give a corrpound [ 1 1 The corrpound III] can be employed in an optional forni, whether as the free compound, as salts with various acids or bases, as esters or as silyl derivatives, for 202507 - }£"- instance. For the compound I III which has substituents at the 3- and 4-positions, there exist the cis- and trans-isomers.
Furthermore, the carbon atoms at the 3- and 4-positions are asyrrrretric carbon atoms. Therefore, there exist theoretically at least 4 stereoisotrers in total. These stereoisomers may be used either alone or in the form of a mixture. The same applies 2 to the case where the group R contains an asymmetric carbon atom. The resulting stereoisotrers may be used either alone or in the form of a mixture.
As the salts of compound [II], there may be used, where the compound [II] has a carboxy1 p group in R , salts with nontoxic cations such as sodium ana potassium, with basic amino acids such as arginine, ornithine, lysine and histidine, and with N-methylglutamine, diethanolamine, tri-ethanolamine, poly(hydroxyalkyl)amines (e.g. tris(hydroxymethyl)aminomethane) and so on. When R contains a basic group, there may be used salts with organic acids such as acetic acid, tartaric acid and methanesulfonic acid, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, salts with acidic amino acids such as arginine, aspartic acid and glutamine, and so forth.
When R contains a carboxyl group, the compound £llj may also be used after conversion to an ester derivative. The ester group in that case includes, among others, a-alkoxy-a-substituted or unsubstituted-methyl groups such as alkoxymethyl and a-alkoxy-ethyl (e.g. methoxymethyl, methoxyethyl, isopropoxymethyl, a-methoxyethyl, a-ethoxyethyl), alkylthiomethyl groups such as methylthiomethyl, ethylthiomethyl and isopropylthiomethyl, acyl-oxymethyl and a-acyloxy-a-substituted-methyl groups such as pivaloyloxymethyl and a-acetoxybutyl, and a-alkoxycarbonato-a- /S -p- 202907 substituted-methyl groups such as ethoxycarbonyloxytrethyl and a-ethoxycarbonyloxyethyl. The compound [II] tray also be used as the starting material in the silylated form produced with the use of a silylating agent. The silylating agent is, for example, a compound of the formula (P1)(P2)(P5)Si.Hal 12 "5 wherein P , P and 7 each is a hydrocarbon group such as a lower alkyl containing 1-4 carbon alkyl (e.g. methyl ethyl, n-propyl, i-propyl, n-butyl) or an aryl (e.g. phenyl, tolyl) and Hal is a halogen atom, preferably a chlorine or bromine atom, and 12 3 wherein one or two of P , P and P each may preferably be a 12 3 chlorine or bromine atom and one of P , P and P may be a hydrogen atom. Furthermore, such silylating agents as hexa(C^ ^)-alkylcyclotrisilazane, octa(C1_^)alkylcyclotetrasilazane, tri-(C^^alkylsilylacetamide and bis-tri(C1_^)alkylsilylacetamide may also be used. As preferred examples of the silylating agent, there may be mentioned silyl compounds of the formula v /{«' I 3 4 '' ' Y - Si - Y si I ---v wherein Y and Y each is a lower alkyl, phenyl, benzyl orlower alkoxy group, Y^ is t-butyl or isopropyl and is a reactive group or atom capable of leaving the silylating agent. In the silylating agents represented by the above general 1 2 formula, the lower alkyl group Y and/or Y is, for example, methyl, chloromethyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl and the lower alkoxy group is, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy or t-butoxy. The reactive group or atom Y^, which is capable of leaving the silylating agent 202.907 includes halogen atoms (e.g. chlorine, bromine), N-(trialkyl-silyl)trifluoroacetimidoyloxy, K-(trialkylsilyl) acetimidoylaxy, acylatrino groups (e.g. f ormylatrino, acetylarrino, propionylamino, butyrylamino, trifluoroacetylairino), (trialkylsilyl )amino groups [e.g. (tri-t-butyldimethylsilyl)amino, isopropyldimethylsilylaminc, (chloromethyldimethylsilyl)amino3, amino, alkylamino groups (e.g. methylamino, ethylamino, propylairino), N,N-dialkylamino groups (e.g. K,N-dimethylamino, N-chloroirethyl-N-methylamino, N,N-diethylamino, N,N-dipropylamino, N-methyl-K-ethylamino, N-methyl-N-propylarrino, N-ethyl-N-propylamino) and heterocyclic groups (e.g. imidazolyl), atrong others. The alkyl troiety in such reactive group or atom represented by Y^ preferably contains 1-4 carbon atoirs and is, for example, irethyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl.
In concrete tenrs, examples of the silyl compound are N,0-bis(t-butyldimethylsilyl)trifluoroacetamide, N,0-bis(isopropyl-dimethyIsilyl)acetamide, bis(dimethylisopropylsilyl)acetamide, isopropyldimethylsilylacetamide, bis(dimethyl-tert-butylsilyl)-acetairide, N-methyl-N-t-butyldimethylsilylacetamide, N-methyl-K-i s opr opy Id iir ethyl silyl trif luoroacetatride, N-t-butyldimethyl-silyldie thy latrine, 1,3-bis(chloromethyl )-1,1, 3» 3-tetra-t-butyl-dime thyld is ilazane, K-isopropyldiirethylsilylimidazole, t-butyl-diphenylchlorosilane, isopropyldiethylchlorosilane, isopropyl-methyldichlorosilane, tert-butyldimethylchlorosilane, isopropylditrethylchlorosilane and t-butyldiethylchlorosilane. When tert-butyldimethylchlorosilane or isopropylditrethylchlorosilane, for instance, is used, the silyl derivative can be isolated in a stable fortr. The silylation reaction is carried out at a temperature of 0°-50°C, preferably at a temperature up to 38°C, mostly at room temperature (about 20°C), for several (about 10) .,1b, - V* - - yi - Z0ZSQ7 minutes to 24 hours. It is convenient to carry out the reaction in a solvent inert to the reaction, such as, for example, ethyl acetate, dioxane, tetrahydrofuran, N,N-dimethylacetamide, N,N-dimethylformamide, dichloromethane, chloroform, benzene, toluene, acetone, methyl ethyl ketone or acetonitrile, or a mixture thereof. The reaction may be carried out in the presence of an inorganic base, such as sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, sodium carbonate or potassium carbonate, or an organic base, such as a trialkylamine (e.g. triethylamine, tributylamine), a triaralkylamine (e.g. tribenzylamine), such an organic tertiary amine as N-methylmorpholine, N-methylpiperidine, N,N-dialkylaniline, N,N-dialkylbenzylamine, pyridine, picoline or lutidine, or 1,5-diazabicyclo [4,3,0]non-5-ene, 1,4-diazabicyclo-12,2,2Joctane or 1,8-diazabicyclo[5,4,4]undecene-7 . When the base is liquid, it may be used also as the solvent. The thus-produced silyl derivative of compound III] is used as the starting material in the step of reaction with a cyano compound, either in the form of a reaction mixture as it is or after isolation/purification by the conventional method such as described hereinbelow.
Among the thus-produced 1-silyl derivatives of compounds [II], those in which the above-mentioned R is a protected amino group may be subjected to protective group elimination and then to acylation so as to give the 1-silyl derivatives of the desired compounds III J. The acylation reaction at position 3 can easily carried out by a simple procedure and give good yields, hence very useful for the synthesis of various 2-oxoazetidinone 15JUL 1985S^rivatives each having the desired acyl group as the substituent. is also possible to carry out the reaction with a cyano compound in a continuous manner directly following the acylation. \b - y! - ZQZ$ 07 As the cyano corrpound, there may be used, for example, a compound of the formula Z - CN wherein Z is an alkali or alkaline earth metal. To be concrete, there may be used, for example, potassium cyanide, sodium cyanide or calcium cyanide.
In this reaction, about 1-3 moles, preferably 1-1.1 moles, of the cyano compound is reacted with 1 mole of compound [IIJ. The reaction is generally carried out in a solvent. Usable solvents are water and common organic solvents, such as ethers (e.g. dioxane, tetrahydrofuran, diethyl ether), esters (e.g. ethyl acetate, ethyl formate), halogenated hydrocarbons (e.g. carbon tetrachloride, chloroform, dichloromethane), hydrocarbons (e.g. benzene, toluene, n-hexane), amides (e.g. dimethylformamide, dimethylacetamide), alcohols (e.g. methanol, ethanol, isopropanol, t-butanol), dimethyl sulfoxide, sulfolane and hexamethylphosphoramide either alone or in admixture. Preferred among these are, for instance, water, dioxane, tetrahydrofuran, carbon tetrachloride, dichloromethane, chloroform, benzene, dimethylformamide, dimethylacetamide, methanol, isopropanol and dimethyl sulfoxide. When the reaction is carried out in the presence of a phase transfer catalyst, the production of those compounds [II] that have the CN group introduced thereinto in the configuration cis to R1 is promoted and more favorable results are obtained. The term "phase transfer catalyst" as used herein means a substance capable of promoting the reaction by rendering one of two reactants ^T^TTr^^eparatedly present in two (liquid-liauid) phases soluble in the ons.
^NV . ^er liquid phase in the ion pair form. A phase transfer 15JUL1985W,talyst adequate for the achievement of the object of the Can be chosen» for instance, from among those which 202907 consist of, on one hand, a cation (ammonium or-phosphonium ion) composed of a nitrogen or phosphorus atom and four groups bonded thereto and each selected from among alkyl, aryl and aralkyl groups and, on the other, an acid residue (anion, such as Cl~, Br", I", P", C104~, BF4~, BH4~, HS04", OH" or H2P04~).
More specifically, there tray be used, for instance, those consisting of a halide ion and an atrtroniutr ion having four substituents which are the same or different and each is selected froir among alkyl, aryl and aralkyl groups, for example, tetraalkyl(total number of carbon atoms 4-50)ammonium halides such as tetramethylammonium chloride, tetraethylammonium chloride, tetra-n-butylammonium chloride, tri-n-octylmethyl-ammonium chloride, trimethylstearylammonium chloride, tetra-n-amyl-ammonium bromide and n-hexyltrimethylammonium bromide, aryltri-alkyl(total number of carbon atoms 9-50)ammonium halides such as phenyltrimethylammonium bromide, and aralkyltrialkyl(total number of carbon atoms 13-50)ammonium halides such as benzyl-dimethyldecylammonium chloride, benzyltriethylammonium chloride and cetylbenzyldimethylammonium chloride; those consisting of HS04~ (hydrogen sulfate ion) and an ammonium ion having four substituents which are the same or different and each is selected from among alkyl, aryl and aralkyl groups, for example, tetra-alkyl(total number of carbon atoms 4-50)ammonium hydrogen sulfates such as tetra-n-butylammonium hydrogen sulfate and tetramethylamironium hydrogen sulfate; those consisting of OH~ A/^^ydroxide ion) and an ammonium ion having four substituents /y wfr-&ch are the same or different and each is selected from atrong 15JULt aryl and aralkyl groups, for example, tetraalkyl(total & p , vi '-- J?-umber of carbon atoms l6-50)ammonium hydroxide such as tetra-n-butylammonium hydroxide; and those consisting of a halide ion 202907 7^ W - and a phosphonium ion having four substituents which are the same or different and each is selected from among alkyl, aryl and aralkyl groups, for example, tetraalkyl(total number of carbon atoms 4-50)phosphonium halides such as tetra-n-butyl-phosphonium bromide, aralkyltriaryl(total number of carbon atoms 9-50)phosphonium halides such as benzyltriphenylphosphonium chloride, and alkyltriaryl(total number of carbon atoms 19-50)-phosphonium halides such as n-butyltriphenylphosphonium bromide. In particular, tri-n-octylmethylammonium chloride, tetra-n-butylammonium hydrogen sulfate, tetra-n-amylammonium bromide, benzyltriethylammonium chloride and tetra-n-butylphosphonium bromide, among others, are used. These phase transfer catalysts are used in an amount of about 0.01-1 mole, preferably 0.05-0.2 mole, per mole of compound [II]. Where a phase transfer catalyst is used, a mixture of water and an organic solvent such as mentioned above is preferably used as the solvent. The mixing ratio is 0.5-5 parts, preferably 0.5-1 part, of the organic solvent per part of water. The reaction temperature is generally within the range of 0-20°C but not limited to this range. Adequate warming or cooling may be made as necessary. While the reaction time is to be adequately selected depending on the solvent, temperature and so forth, the reaction generally comes to an end in a short period of time.
After the reaction, the compound II] produced can be recovered in any desired purity by a per se known isolation/purification method, such as solvent extraction, recrystallization or chromatography, although the reaction mixture as it is may also e used as the starting material in the next reaction step.
JULI985 202907 - & - When the thus-obtained compound [I] has a protective group, the protective group iray be eliminated as necessary. The method of eliminating the protective group can adequately be selected,depending on the nature of the protective group, from the conventional methods, such as the method using an acid, the method using a base, the method involving reduction, and the method using thiourea or sodium N-methyldithiocarbamate. In the method using an acid, the acid, which should be selected depending on the kind of the protective group and other factors, is, for example, such an inorganic acid as hydrochloric, sulfuric or phosphoric acid, such an organic acid as formic, acetic, trifluoroacetic, propionic, benzenesulfonic or p-toluenesulfonic acid, or an acidic ion exchange resin. In the method using a base, the base, which is to be selected depending on the kind of the protective group and other conditions, is, for example, such an inorganic base as an alkali metal (e.g. sodium, potassium) or alkaline earth metal (e.g. calcium, magnesium) hydroxide or carbonate, a metal alkoxide, such an organic base as an organic amine or a quaternary ammonium salt, or a basic ion exchange resin. When a solvent is used in conducting the above method using an acid or base, the solvent is mostly a hydrophilic organic solvent, water, or a mixture of these. In the method involving reduction, the method of reduction, though depending on the protective group species and other conditions, is, for example, the method using a metal (e.g. tin, zinc) or a metal compound (e.g. chromiun dichloride, chromium acetate) in combination with an organic or organic acid (e.g. propionic acid, hydrochloric acid), or the hod involving reduction in the presence of a metal catalyst catalytic reduction. The catalyst to be used in said catalytic 202907 7.1. - &L - reduction includes, among others, platinum catalysts such as platinum wire, platinum sponge, platinum black, platinum oxide and colloidal platinum, palladium catalysts such as palladium sponge, palladium black, palladium oxide, palladium-on-bariurr oxide, palladium-on-barium carbonate, palladium-on-carbon, pal-lad iutr-on-silica gel and colloidal palladium, and reduced nickel, nickel oxide, Raney nickel and Urushibara nickel. In the reduction method using a metal and an acid, such a metal compound as iron or chromium and such an inorganic acid as hydrochloric acid or such an organic acid as formic, acetic or propionic acid are used. The method involving reduction is generally carried out in a solvent. Thus, for example, in the catalytic reduction, such alcohols as methanol, ethanol, propyl alcohol and isopropyl alcohol, and ethyl acetate, among others, are used frequently. In the method using a metal and an acid, water and acetone, among other, are frequently used and, when the acid is liquid, the acid itself can be used also as the solvent. The reaction is generally carried out with or without cooling or warming. The thus-produced compound [II] can be isolated and purified by a known method such as mentioned above although the reaction mixture itself can be used as the starting material in the next reaction step. p When R in the thus-obtained compound III is an amino group, the compound 11 J may optionally be acylated by reaction with a carboxylic acid of the formula R°COOH [IV] o *1 wherein R CO is such an acyl group as mentioned for R R^, or a functional derivative thereof.
R2 and 73 - >Z - 202907 2 The corrpound [I] in which R is an amino group tray be used in the free fortr or in the forrr of a salt, ester or silyl derivative such as irentioned for the compound [IIJ . The functional derivative of the carboxylic acid [ IV ] is, for exatrple, an acid halide, acid anhydride, active atride or active ester. Examples of such functional derivative of the organic acid are as follows: 1) Acid anhydrides The acid anhydrides include, airong others, trixed acid anhydrides with hydrogen halides (e.g. hydrogen chloride, hydrogen bromide), trixed acid anhydrides with tronoalkyl carbonates, trixed acid anhydrides with aliphatic carboxylic acids (e.g. acetic acid, pivalic acid, valeric acid, isopentanoic acid, trichloroacetic acid), trixed acid anhy The active atrides include, atrong others, airides with imidazole, 4-substituted imidazoles, dimethylpyrazole and benzotriazole. 3) Active esters The active esters include, among others, methyl, ethyl, methoxymethyl, prdpargyl, 4-nitrophenyl, 2,4-dinitrophenyl, trichlorophenyl, pentachlorophenyl and mesylphenyl esters and further esters of such carboxylic acids as mentioned above with 1-hydroxy-1H-2-pyridone, N-hydroxysucciniiride, N-hydroxy-5-norbornene-2,3-dicarboximide and N-hydroxyphthalimide.
An adequate functional derivative of the organic acid can be selected from airong those mentioned above depending on the kind of acid to be used. Furthermore, when an acid in the carboxylic acids (e.g. benzoic acid), anhydrides. 2) Active amides -2.Y 202907 free form is used as the acylating agent, the reaction is preferably carried out in the presence of a condensing agent. The condensing agent is, for example, N,N'-dicyclohexylcarbo-diimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclo-hexyl-N'-(4-diethylaminocyclohexyl)carbodiimide or N-ethyl-N1-(3-dimethylaminopropyl)carbodiimide.
Said acylation reaction is generally carried out in a solvent. Usable solvents are water, acetone, dioxane, aceto-nitrile, methylene chloride, chloroform, dichloroethane, tetrahydrofuran, ethyl acetate, dimethylformamide, pyridine and other common organic solvents inert to the reaction. Hydro-philic solvents may be used in admixture with water.
Furthermore, the acylation reaction may be carried out in the presence of such an inorganic base as sodium hydroxide, sodium carbonate, potassium carbonate or sodium hydrogen carbonate, or such an organic base as trimethylamine, triethyl-amine, tributylamine, N-methylrrorpholine, N-methylpiperidine, a like triaIky1 amine, N,N-dialkylaniline, N,N-dialkylbenzyl-amine, pyridine, picoline, lutidine, a like organic tertiaty amine, 1,5-diazabicyclo[4,3,0]non-5-ene, 1,4-diazabicyclo-[2,2,2]octane or 1,8-diazabicyclo[5,4,4]undecene-7. The base or the above-mentioned condensing agent, if liquid, may be used also as the solvent. The reaction temperature is not critical, but in most cases the reaction is generally carried out under cooling or at room temperature.
Furthermore, when the compound [I] and/or the acylating r/k N ^elgent [II] contains an asymmetric carbon atom or atoms, the "m acylation may be carried out using the reactant either in the 15JUL19853i of stereoisomer or in the form of a mixture of stereo- ' 7^>' - 24 - 202907 isomers. If the reaction leads to formation of a mixture of stereoisomers, the isomers can respectively be isolated as necessary by a conventional method such as chromatography or recrystallization. When the thus-obtained compound [I] (where 2 R N^) has a protective group, said group can be eliminated as necessary in the same manner as mentioned above. Furthermore, the compound [I] obtained in the above manner in which W is a hydrogen atom may also be sulfonated.
The sulfonation just mentioned above refers to the introduction of a sulfo group into the compound II] (where W=H) at the 1-position and is carried out, for instance, by reacting the compound [I] (where W=H) with sulfur trioxide or a reactive derivative of sulfur trioxide, among others. The compound [I] (where W=H) is used in the free form or in the form of a salt, ester or silyl derivative such as mentioned for the compound [II], and may be subjected to the reaction either in the form of a theoretically possible individual stereoisomer or in the form of a mixture of stereoisomers. The reactive derivative of sulfur trioxide includes, among others, such adducts as sulfur trioxide-base complexes (.e.g. sulfur trioxide-pyridine, sulfur trioxide-trimethylaraine, sulfur trioxide-picoline, sulfur trioxide-lutidine, sulfur trioxide-N,N-dimethyl-formamide), sulfur trioxide-dioxane and sulfur trioxide-chlorosulfonic acid.
The above sulfonation reaction is carried out using about 19GUL1985m$_10 moles, preferably about 1-5 moles, of sulfur trioxide or a reactive derivative thereof per mole of compound [I] (where W=H). The reaction temperature is about -78 to about 80°C, preferably about -20 to about 60°C. The reaction may be carried out in a solvent. Usable solvents include water and common organic solvents, for example, such ethers as dioxane, tetra- 202907 Uo >5 - hydrofuran and diethyl ether, :such esters as ethyl acetate and ethyl formate, such halogenated hydrocarbons as chloroform and dichloromethane, such hydrocarbons as benzene, toluene and n-hexane, and such amides as N,N-dimethyIformamide and N,N-dimethylacetamide. Such solvents are used each alone or in admixture. The reaction is generally complete in several tens of minutes to scores of hours, in some cases in scores of days, depending on the starting compound [I] (where W = H) , sulfonating agent, reaction temperature and solvent. After the reaction, the reaction mixture is subjected to a per se known purification/isolation procedure, such as solvent extraction, recrystallization or chromatography, to give the compound [I] (where W=SO^H) in any desired purity. When there is a protective group, said group may be eliminated by a method such as mentioned above.
The thus-obtained compound [I], when in the free form, may be converted to a salt or ester such as mentioned for the compound [II] by a conventional method. Conversely, when the compound [I] is obtained in the salt or ester form, the salt or ester may be converted to the free form by a conventional method.
The thus-obtained 4-cyano-2-azetidinone derivatives [I] are novel compounds and can be used widely as advantageous ^intermediates for the synthesis of various 4-substituted-2-tetidinone derivatives. Moreover, those compounds where t 5 JUL 1985^ S03H bave antimicrobial and beta-lactamase inhibiting 'V activities. i ~~ Compounds [III] are produced, for example, by subjecting a compound [I] (W=H) to hydration, followed by protective group 202907 JUL I985°l! >C° p." elimination as necessary. This hydration reaction converts the cyano group in the compound [I] (W=H) into a carbamoyl group. The starting compound [I] (W=H) may be in the free form or in the salt, ester or silyl derivative form such as mentioned for the compound [II]. For the compound [I] (W=H) which has substituents at the 3- and 4-positions, there occurs cis-trans isomerism and moreover the carbon atoms in the 3- and 4-positions are asymmetric. As a result, there can theoretically exist a total of at least four stereoisomers for each compound [I].
These stereoisomers may be used either each alone or in the form of a mixture. The same may be said of the case where the group R^" contains an asymmetric carbon atom or atoms, and the resulting stereoisomers also may be used either each alone or in the form of a mixture.
The hydration reaction is carried out by any method by which the cyano group in position 4 of the compound [I] (W=H) is converted to a carbamoyl group, for example, the method comprising reacting the compound [I] (W=H) with an acid or base, or the method comprising reacting the compound [I] (W=H) with hydrogen peroxide in the presence of a base. Examples of said base are alkali metal (e.g. lithium, potassium, sodium) or alkaline earch metal (e.g. calcium, magnesium) hydroxides (e.g. potassium hydroxide, sodium hydroxide, lithium hydroxide, calcium hydroxide, magnesium hydroxide) and carbonates (e.g. sodium ^jparbonate, potassium carbonate, calcium carbonate), like inorganic bases, metal alkoxides (e.g. sodium methylate, sodium ethylate), organic amines (e.g. triethylamine, N,N-dimethyl-aniline, diisopropylamine), quaternary ammonium salts (e.g. tetra-n-butylammonium hydroxide), like organic bases, and Xfr e <& 202907 ~P" basic ion exchange resins. Among them, alkali metal hydroxides (e.g. sodium hydroxide) are frequently used as preferred bases. The acid includes, among others, such inorganic acids and salts as hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, ferric chloride, zinc chloride, manganese dioxide, boron trifluoride, palladium chloride and titanium tetrachloride, such organic acids as formic acid, acetic acid, p-toluenesulfonic acid and trifluoroacetic acid, silica gel and acidic ion exchange resins. Especially preferred among them are such acids as hydrochloric acid, sulfuric acids, manganese dioxide, palladium chloride and titanium tetrachloride. These acids or bases are used generally in an amount of 0.1-4.0 moles, preferably 0.1-1.0 mole, per mole of compound [IJ (W=H). When hydrogen peroxide is used, the bases are used in an amount of 0.05-4.0 moles, preferably 0.05-1.0 mole, per mole of compound [I] (W=H). Hydrogen peroxide is used in an amount of 1.0-10 moles, preferably 1.0-4 moles, per mole of compound [I] (W=H). This reaction is generally carried out in a solvent. Usable solvents are, for instance, water, ethers (e.g. tetrahydrofuran, dioxane), acid amides (e.g. N,N-dimethyIformamide, N,N-dimethylacetamide), hydrocarbons (e.g. benzene), ketones (e.g. acetone), alcohols (e.g. methanol, ethanol, propanol, butanol), halogenated hydrocarbons (e.g. chloroform, dichloromethane), fatty acids (e.g. formic acid, acetic acid), esters (e.g. ethyl acetate), dimethyl sulfoxide, sulfolane and hexamethylphosphoramide, and mixtures of these. Among these, frequently used are water, isopropanol, tetrahydrofuran, dichloromethane, dimethyl sulfoxide and * / -^fche like. When a mixture of water and an organic solvent is -n\\ 1&JULl985<vjsed as t*16 solvent, the reaction may be carried out in the 7~°\ - - 202307 presence of a phase transfer catalyst. The phase transfer catalyst may be the one as mentioned hereinbefore in connection with the reaction of a compound [II] and a cyano compound. The phase transfer catalyst is used in an amount of about 0.1-2 moles, preferably 0.5-1 mole, per mole of compound [I](W=H). The reaction temperature is generally selected within the range of 0-80°C but is not limited thereto. Thus, the reaction may be conducted with adequate warming or cooling as necessary. The reaction is complete generally in a short period of time.
After the reaction, the reaction mixture is subjected to a per se known purification/isolation procedure, such as solvent extraction, recrystallization or chromatography, to give a compound [III] in any desired purity. The reaction mixture as it is may also be used as the starting material in the next reaction step. When this reaction leads to formation of isomers, the respective isomers may be isolated as necessary by a conventional method, and, when the substituent of the compound [III] has a protective group, said group may be eliminated as necessary in the same manner as mentioned above.
The thus-obtained compound [III] can evidently be sulfonated in the same manner as the sulfonation of compound [I] (where W=H) , to give the corresponding compound [III] where has a sulfo group at 1-position.
When the thus-produced compound [III] is in the free form, it may be converted to a salt or ester such as mentioned above a conventional method. When the compound [III] is obtained Tjn the salt or ester form, it may be converted to the free corm by a conventional method. 202907 The compounds I III] which have SO^H at I-position are novel compounds and have excellent antibacterial and beta-lactamase inhibiting activities U.K.Patent Specification No: 2091724 and European No: 53816.
Furthermore, the compound [I] , when reacted with hydrogen sulfide, gives a compound having a -CSNH^ group in place of the cyano group at the 4-position of compound [I]. This reaction is preferably carried out using about 1.0-3 moles of hydrogen sulfide per mole of compound [I] or salt, ester or silyl derivative thereof. The reaction is advantageously conducted at or below room temperature, preferably in a solvent such as, for example, chloroform, dichloromethane, benzene, ethyl acetate, tetrahydrofuran, dioxane, N,N-dimethylformamide, N,N-dimethyl-acetamide, dimethyl sulfoxide, acetic acid or water. Generally, the reaction is complete in a short period of time.
Furthermore, the reaction of the compound [I] with an alcohol such as methanol or ethanol gives a compound having an alkoxycarbonyl group in place of the cyano group at the position 4 of compound [I]. In that reaction, an at least equimolar amount of alcohol to the compound [I] is used and in many cases the alcohol itself is used as the solvent. When a solvent is used, the solvent is preferably selected from among such solvents as chloroform, dichloromethane, benzene, tetrahydrofuran, dioxane, N,N-dimethylformamide, N,N-dimethylacetamide and dimethyl sulfoxide. The reaction temperature is generally within the range of 0-80°C, but not limited to this condition. Thus, the ^•reaction may be carried out with adequate warming or cooling as necessary. The reaction time and other conditions depend on 3\ -ja - 202907 the solvent and temperature employed, among others. Copresence of such an inorganic acid as sulfuric, hydrochloric or phosphoric acid, such an organic acid as acetic or p-toluenesulfonic acid or such a Lewis acid as aluminum chloride, zinc chloride or boron trifluoride may result in a reduced reaction time.
The starting compounds [II] to be used in accordance with the invention can be prepared, for example, by the process mentioned hereinbelow. Thus, the starting compounds [II] can be prepared, for example, by the method described in Tetrahedr* Patent Specifications 2012766 & 2065656 Latters, 4059 (1978) or OLS U.K. / or a modification tnereof, or by the method described, for example, in Annalen der Chemie, 1974, 539. These synthetic methods can be illustrated in the following by routes 1) and 2). 1) X OAc R' y <y Nil C V J Substitution reaction X H' c/ NH 2) X OAc R20 Nil C VI j Protective group elimination h2n X I c/ OAc / X OA Nil Acylation (VII5 Substituti reaction In each of the above formulas, R , Y and X are as defined ij 20 21 ^above, R is a protected amino group and R is an acylated amino group. -z1 - 202907 The following examples and reference examples illustrate the present invention in more detail. The NMR spectra were recorded on a Varian model HA 100 (100 MHz) with tetramethyl-silane as a standard, and the 6 values are given in ppm. The abbreviation s stands for singlet, br. s. for broad singlet, d for doublet, dd for double doublet, t for triplet, q for quartet, m for multiplet, ABq for AB-pattern quartet, J for coupling constant, THF for tetrahydrofuran, DMF for dimethyl-formamide, DMSO for dimethyl sulfoxide, br. or broad for broad, and arom for aromatic In the following examples and reference examples, the silica gel column chromatography was performed, unless otherwise stated, using Art. 9385, 230-400 mesh, Kiesel Gel 60 (Merck) and those fractions which, in TLC analysis, gave a spot having the same R^ value as that for the main spot as found newly upon TLC analysis of the crude product before chromatographic purification were collected. The TLC was carried out, unless otherwise stated, using Art. 5642 HPTLC Kiesel Gel 60 (Merck) plates and the same developing solvent as used in the column chromatography, with a UV detector. The XAD-II (100-200 mesh) column chromatography was performed using water-to-20% aqueous ethanol as the developing solvent system, and the fractions showing an absorption at 254 nm (as measured with a Swedish LKB UVI CORD 2) were collected and lyophilized to give a purified product. - 202907 Best Mode for Working the Invention Example 1 In 2 ml of dimethylformamide was dissolved 0.488 g of (3S, 4S)-4-cyano-3-[D-2-(4-ethyl-2,3-dioxo-l-piperazinecarbox-amido)-2-(thiophen-2-yl)]acetamido-2-azetidinone. To the solution was added at -70°C 3.5 ml of dimethylformamide containing 0.536 g of a complex of sulfuric anhydride and dimethylformamide, and the reaction was allowed to proceed at 0°C for two days. The reaction solution, to which was added 0.5 ml of pyridine, was subjected to concentration under reduced pressure. To the residue was added water, and insolubles were removed by filtration. The filtrate was allowed to pass through a column of Dowex 5 0 Na-type (manufactured by Dow-Chemical, Co.), which was purified by means of a column of Amberlite XAD-II (manufactured by Rohm & Haas, Co.) to yield 0.350 g of sodium (3S, 4S)-4-cyano-3-[D-2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido)-2-(thiophen-2-yl)J-acetamido-2-azetidinone-l-sulfonate.
IRvmaxCIn~1: 1780' 1710, 1675, 1510, 1280, 1260, 1050 NMR (DMSO-dg, ppm) : 1.10 (t, J=5Hz, CH-j), 3.41 (q, J=5Hz, -CH2-), 3.60 (m, -CH2~) , 3.93 (m, -CH2-), 4.90 (d, J=4Hz, C4-H), 5.30 (dd, J=4, 8Hz, C^-H), 5.83 Cd, J=4Hz,-CH- ), 6.90-7.60 I (m, aromH), 9.76 (d, J=4Hz, NH), 9.83 (d, J=8Hz, NH) Example 2 1) In 2 ml of DMF was dissolved 0.220 g of (3S, 4S)-3-[2-(2-chloroacetamidothiazol-4-yl)-2-methoxyimino]acetamido-4-cyano-2-azetidinone. To the solution was added at -70°C 1.8 ml of a DMF solution containing 0.275 g of a complex of sulfuric anhydride and DMF, and the reaction was allowed to proceed at 0°C for three days. The reaction solution, to >202 J 07 which was added 0.5 ml of pyridine, was treated in a manner analogous to that of Example 1 to yield 0.170 g of sodium (3S, 4S)-3-12-(2-chloroacetamidothiazol-4-yl)-2-methoxyimino] acetamido-4-cyano-2-azetidinone-l-sulfonate.
IRvKBrcm_1: 1780, 1670,1540, 1260, 1055 max NMR(D20, external standard, ppm): 4.04 (s, och3), 4.44 (s, -CH2-), 5.26 (d, J=5Hz, C4~H), 5.46 (d, J=5Hz, 2) In 6 ml of water was dissolved 0.150 g of the chloroacetamido compound. To the solution was added under ice-cooling 0.050 g of sodium monomethyldithiocarbamate, and the mixture was stirred at room temperature (about 25°C) for three hours. The reaction solution was purified on a column of XAD-II to yield 0.067 g of sodium (3S, 4S)-3-[2- (2-aminothiazol-4-yl]-2-methoxyimino]acetamido-4-cyano-2-azetidinone-l-sulfonate.
NMR(D20, external standard, ppm): 4.00 (s, OCH-^), 5.24 ( 1) In 2 ml of DMF was dissolved 0.482 g of (3S, 4R)-3-{2- (2-chloroacetamidothiazol-4-yl)-2-methoxyimino]acetamido-4-cyano-2-azetidinone. To the solution was added at -70°C 3.9 ml of a DMF solution containing 0.5 97 g of a complex of sulfuric anhydride and DMF, and the reaction is allowed to proceed at 0°C for two days. The reaction solution, to which was added 0.5 ml of pyridine, was treated in a manner similar to that of Example 1 to yield 0.390 g of sodium (3S, 4R) -3-[2-(2-chloroacetamidothiazol-4-yl)-2-methoxyimino]-acetamido-4-cyano-2-azetidinone-l-sulfonate.
IRv^Brcm~1: 1780, 1665, 1610, 1520, 1260 ItlclX 1050 d, J=5Hz, C4-H), 5.45 (d, J=5Hz, C3~H) 7.06 Example 3 -,x- 202907 TT. KBr -1 1 max™ : 1785, 1670, 1550, 1260, 1055 NMR(D20, external standard, ppm): 4.06 (s, OCH3), 4.44 (s, -CH2-), 5.14 (d, J=2Hz, C4~H), 5.40 (d, 3-2HZ, C3-H) , 7.43 (s, SN/) Y 2) In 6 ml of water was dissolved 0.190 g of the chloroacetamido compound. The solution was treated in a manner similar to that of Reference Example 2, 2) while using 0.052 g of sodium monomethyldithiocarbamate to thereby yield 0.074 g of sodium (3S, 4R)—3—[2—(2—aminothiazol— 4-yl)-2-methoxyimino]acetamido-2-azetidinone-l-sulfonate.
To a mixture of 1.196 g of D-2-(4-ethyl-2,3-dioxo-l-piperazinocarboxamido)-2-(thiophen-2-yl)acetate, 20 ml of methylene chloride and 0.530 g of triethylamine was added 0.775 g of puluverized phosphorus pentachloride with stirring under ice-cooling. The mixture was stirred for one hour under ice-cooling, which was concentrated under reduced pressure. To the concentrate was washed by several times of decantation by the addition of n-hexane. To the residue was added dry tetrahydrofuran to remove the insolubles.
On the other hand, 0.992 g of p-toluenesulfonate of (3S, 4S)-3-amino-4-cyano-2-azetidinone was dissolved in 15 ml of dry tetrahydrofuran. To the solution was added under ice-cooling 1.060 g of triethylamine, to which was further added the tetrahydrofuran solution of acid chloride prepared as above. The mixture was stirred at-room temperature (about 25°C) for 40 minutes, which was concentrated under reduced pressure. The concentrate was subject "" ' " :a- : 1780, 1660, 1615, 1520, 1280, 1250, 1050 NMR(D20, external standard, ppm): 4.02 (s, och3), 5.12 (d J=3Hz, C4-H), 5.37 (d, J=3Hz, C3-H), 6.96 (s, ) Example 4 -pr- 202907 gel column chromatography [developer, ethyl acetate: chloroform: methanol (3:3:1)] to yield 0.560 g of (3S, 4S)-4-cyano-3-[D-2-(4^ethyl-2,3-dioxo-l-piperazinocarboxamido)-2-(thiophen-2-yl) ] acetamido-2-azetidinone IRvKBrcm""1: 1785, 1710, 1670, 1500 max ' NMR(DMSO-dg, ppm): 1.09 (t, J=5Hz, CH3), 3,40 (q, J=5Hz, -CH2-_, 3.56 (m, -CH2~) , 3.90 (m, -CH2-), 4.76 td, J=4Hz, C4-H), 5.30 (dd, J=8, 4Hz, C3-H), 5.83 (d, J=4Hz, -CH-), 6.90-7.60 (m, arom H), 9.03 (br. s, NH), 9.70 (d, J=4Hz, NH), 9.80 (d, J=8Hz, NH) In 15 ml of dry tetrahydrofuran was suspended 0.960 g of p-toluenesulfonate of (3S, 4S)-3-amino-4-cyano-2-azetidinone. To the suspension were added under ice-cooling 1.4 00 g of triethylamine, to which was added 10 ml of dry tetrahydrofuran in which was dissolved 2-(2-chloroacetamido-thiazol-4-yl)-2-methoxyiminoacetyl chloride hydrochloride. The mixture was stirred at room temperature (about 25°C) for 30 minutes. The reaction solution was cocentrated under reduced pressure. The concentrate was subjected to a silica-gel column chromatography [developer, ethyl acetate: chloroform: methanol (3:3:1)J to yield 0.910 g of (3S, 4S)-3-[2-(2-chloroacetamidothiazol-4-yl)-2-methoxyimino]acetamido-4-cyano-2-azetidinone.
Example 6 In 10 ml of dry tetrahydrofuran was suspended 0.540 g of p-toluenesulfonate of (3S, 4R)-3-amino-4-cyano-2-azetidinone.
Example 5 IRvKBrcm-1: 1790, 1675, 1540, 1050 max NMR(DMS0+D20, ppm): 3.93 (s, OCH3), 4.33 (s, -CH2-) , 4.83 (d, J=4Hz, C4~H) . 5.40 (d, J=4Hz); C3-H), 7,46 (s, S H x I in - X- 202907 To the suspension were added under ice-cooling 0.787 g of triethylamine, to which was added 5 ml of dry Tetrahydrofuran in which was dissolved 0.600 g of 2-(2-chloracetamidothiazol-4-yl)-2-methoxyiminoacetyl chloride hydrochloride. The mixture was stirred at room temperature (about 25°C)for 30 minutes. The reaction solution was subjected to a silica gel column chromatography [developer, ethyl acetate: chloroform: methanol (3:3:1)] to yield 0.525 g of (3S, 4R)-4-cyano 3-[2-(2-chloroacetamidothiazol)4-yl)-2-methoxyimino]acetamido-2-azetidinone.
In 100 ml of methylene chloride were dissolved under ice-cooling 5 g of p-toluenesulfonate of (3S, 4RS)-3-amino-4-cyano-2-azetidinone and 4.2 g of pyridine. To the solution was added 3 g of phenylacetyl chloride. The mixture was stirred at room temperature (about 25°C) for ten minutes, which was shaken with water. The organic layer was separated and dried on anhydrous magnesium sulfate, then concentrated under reduced pressure. The concentrate was purified on a silicagel column chromatography [ethyl acetate: n-hexane (2:1)] to yield 1.16 g of (3S, 4S)-4-cyano-3-phenylacetamido-2-azetidinone (A) and subsequently 0.84 c of a corresponding (3S-4R)-derivative (B).
IRvKBrcm"1s 1780, 1670, 1540, 1040 max Example 7 // (A) IRv^cm"1: 2250, 1770, 1665, 1530 1350 max NMR(DMSO-dg, ppm): 3.60 (s, -CH2~), 4.20 (d J=4Hz, C4-H), 4.86 (dd, J=4, 8Hz, C3~H), 6.56 (d, J=8Hz, NH), 7.26 (s, arom H) KBr -1 - yl - 202907 (B) IRvKBrcm"1: 2250, 1780, 1660, 1520, 1350 max NMR(DMSO-dg, ppm): 3.60 (s, -CH2~), 4.10 (d, J=2Hz, C4-H) , 4.80 (dd, J=2, 8Hz, C-j-H) , 6.60 (d, J=8Hz, NH) , 7.20 (s, arom H) Example 8 A mixture of 1.66 g of p-toluenesulfonate of (3S, 4R)-3-amino-4-cyano-2-azetidinone, 0.5 g of pyridine and 5 ml of methylene chloride was stirred at room temperature for 15 minutes. To the mixture, while stirring under ice-cooling, were added 10 ml of propylene oxide and subsequently 1.1 g of 2-trimethylsilylethoxycarbonylchloride, followed by stirring at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure, and the concentrate was subjected to a silicagel column chromatography [developer, ethyl acetate: n-hexane (1:1)] to yield 1.0 g of (_3S, 4R1 *-4-cyano-3-(2-trimethylsilyl) -ethoxycarboxamido-2-azetidinone.
IRvfllcm~1: 2950, 1885, 1710, 1510, 1250, mdx 860, 840 NMR(CDC13, ppm): 0.03 (s, CH3), 1.00 (t, J=8Hz, -CH2-), 4.20 (t, J=8Hz, —CH2—), 4.60 (d, J= 2Hz, C4-H), 5.33 (dd, 3=2, 8Hz, C3~H), 5.70 (d, J=8Hz, NH), 6.80 (br. s, NH) Example 9 In 50 ml of tetrahydrofuran was suspended 11.2 g of p-toluenesulfonate of (3S, 4RS)-3-amino-4-cyano-2-azetidinone. To the suspension was added under ice-cooling, 5 g of triethylamine, which was stirred for 30 minutes, followed by concentration under reduced pressure. To the consentrate were added 20 ml of methylene chloride and 80 ml of propyleneoxide to make a solution. To the solution was added 6.8 g of carbobenzoxychloride unde 15JUL /%5 of "j/ - ZQZ907 ice-cooling/ which was stirred at 25°C for 30 minutes, followed by concentration under reduced pressure. To the concentrate were added ethyl acetate and water, and the mixture was shaken. The organic layer was taken, washed with water, and dried on anhydrous magnesium sulfate, followed by concentration under reduced pressure. The concentrate was purified on a 150 g silicagel column [developer, ethyl acetate: n-hexane (1:1)] to yield 2.1 g of (3S, 4R)-3-benzyloxycarboxamido-4-cyano-2-azetidinone as an oily substance and, subsequently, 3.21 g of (3S, 4S)-4-cyano-3-benzyloxycarboxamido-2-azetidinone as crystals. (_3S, 4S)-form mp 167-170°C (dec.) VDv _ 1 3380, 3260, 2245, 1805, 1765, T_, KBr -1 IRv cm max 1675, 1525 NMR(DMSO-dg, ppm): 4.50 (d, J=5Hz, C4~H), 5.10 (s, -CH2-), 5.16 (dd, J=5, 8Hz, C3~H), 7.26 (s, arom H), 8.16 (d, J=8Hz, NH), 8.56 (broad s, NH) Example 10 1) In 15 ml of THF was dissolved 0.298 g of (3R, 4R)-3-benzyloxycarboxamido-4-methylsulfonyl-2-azetidinone.
To the solution was added 0.25 g of palladium black, and the mixture was stirred for two hours in hydrogen streams. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure until the volume was reduced to about 3 ml.
On the other hand, to 10 ml. of methylene chloride was added 0.555 g of 2-(2-chloroacetamidothiazol-4-yl)-2-methoxyiminoacetic acid (syn-isomer). To the mixture were added, under ice cooling, 0.25 g of triethylamine, then 0.4 2 g of phosphorus pentachloride, and the whole mixture was stirred for five minutes, which was further stirred for 10 minutes at room temparature, followed by concentration 5 JUL 1985 £junder reduced pressure. The residue was washed with n-hexane 202907 to which was added 5 ml of THF, then resulting insolubles was removed by filtration. The filtrate was added, under ince-cooling, to a mixture of the solution prepared as above and 1 ml of propylene oxide. The solvent was removed by distillation, and the residue was dissolved in ethyl acetate. The ethyl acetate solution was washed with water, which was concentrated under reduced pressure. The concentrate was purified on a silicagel column [n-hexane-ethyl acetate (1:1)J to yield 0.13 g of (3R, 4R)-3-[2-(2-chloroacetamidothiazol-4-yl)-2-methoxyiminoacetamido]-4-methylsulfonyl-2-azetidinone.
IRvKBrcm-1: 3370, 3270, 1790, 1680, 1540 max ' NMR(DMSO-dg, ppm): 3.00 (s, CH3), 3.93 (s, CH3), 4.33 (s, -CH2-), 4.93 (d, J=5Hz, C4~H), 5.57 (dd, J=5, 9Hz, C3-H) , 7.53 (s,^-H), 8.30 (d, J=9Hz, NH) , 9.40 (s, NH), 12.73 (s, NH) 2) In 3 ml of DMF was dissolved 0.46 g of (3R, 4R)-3-[2-(2-chloroacetamidothiazol-4-yl)-2-methoxyiminoacetamido]-4-methylsulfonyl-2-azetidinone. To this solution was added 0.3 6 g of a complex of sulfuric anhydride and pyridine, and the reaction was allowed to proceed for 12 days. To the reaction mixture was added ether, and the separating oily substance was washed with ether. The oily sustance was dissolved in water, to which was added 10 ml of sodium-type Dowex 50 W resin (manufactured by Dow Chemical Co.) . The mixture was stirred fo 30 minutes. The resin was removed by filtration, and the filtrate was purified on a column packed with XAD-II resin (manufactured by Rohm & Haas Co.) to yield 0.023 g of sodium (3R, 4R)-3-[2-(2-chloroacetamidothiazol-4-yl)-2-methoxyiminoacetamido] -4-methylsulfonyl-2-azetidinone-1-sulfonate. - - 202907 $ IRvKBrcin~1: 3450-3400, 1785, 1685, 1672, max 1280, 1260, 1052 NMR(DMSO-dg, ppm): 3.84 (s, CH3), 4.33 (s, -CH2~), 5.15 (d, J=5Hz, C4-H), 5.71 (dd, J=5, 9Hz, C-j-H), 7.53 (s,>-H), 9.45 (d, J=9Hz, NH) , 12.88 (s, NH) Example 11 In 12 ml of tetrahydrofuran was dissolved 0.30 g of (3R, 4S)-3-amino-4-cyano-2-azetidinone-p-toluenesulfonate. To the solution were added, under ice-cooling, 0.12 g of triethylamine and, subsequently 0.60 g of 2-(2-chloroacetamido-thiazol-4-yl)-2-(1-p-nitrobenzyloxycarbonyl-l-methylethoxy-imino)acetyl chloride hydrochloride. The mixture was stirred at room temperature for 4 0 minutes, followed by concentration under reduced pressure. The residue was purified on a silicagel column lethyl acetate-chloroform-methanol (3:3:1)J to yield 0.27 g of (3S, 4S)-3-[2-(2-chloroacetamidothiazol-4-yl)-2- (1-p-nitrobenzyloxycarbonyl-1-methylethoxyimino)acetamido]-4-cyano-2-azetidinone.
IRvKBrcm_1: 1785, 1740, 1675, 1530 max t Example 12 In 850 ml of an aqueous solution of tetrahydrofuran (1:1) was dissolved 100 g of p-toluenesulfonate of (3S, 4S)-3-arr1ino-4-cyano-2-azetidinone. To the solution was added gradually, under stirring, 74.1 g of sodium hydrogen carbonate at a temperature not higher than 10°C. To the mixture was added carbobenzoxy chloride at 3-5°C in the course of 4 0 minutes, followed by stirring for 30 minutes at the same temperature. To the reaction mixture was added 300 ml. of ethyl acetate, and the mixture was shaken. The resulting ethyl acetate layer was separated. The aquenous layer was subjected to extraction with ethyl acetate. The extract o I -fC- 202907 solution was combined with the organic layer, washed with water, and dried on anhydrous magnesium sulfate, followed by concentration under reduced pressure. The precipitating crystals were collected by filtration to afford 34 g of (3S, 4S)-4-cyano-3-benzyloxycarboxamido-2-azetidinone. IR and NMR spectra of this compound are in agreement with those of the compound obtained in Example 9. & -y. 20Z90J Example 13 1) To a solution of 12.3 g of (3R,4R)-4-methyl-sulfonyl-3 - tritylamino-2-azetidinone in 150 ml of DMF is added a solution of 1.6 g of potassium cyanide in 24 ml of water under ice-cooling and the mixture is stirred at room temperature (approx. 25°C) for 30 minutes.. To the reaction mixture are added ice water and ethyl acetate,and the ethyl acetate layer is taken, washed with water and dried over anhydrous magnesium sulfate. The solvent is then distilled off under reduced pressure and the residue is chromato-graphed on a silica gel column [eluant: ethyl acetate-n-hexane (1:1)J to give 6.7 g of (3S,4RS)-4-cyano-3-tritylamino-2-azetidinone (4R:4S = 1:1).
KRt* —1 IRV cm : 2230, 1770. max 2) To a solution of 10.6 g of (3S,4RS)-4-cyano-3-tritylamino-2-azetidinone thus obtained in 1) in 20 ml of acetone is added 6.3 g of p-toluenesulfonic acid monohydr^te to give a uniform solution. The resultant crystalline (\ J 5 J|JL J985 precipitate is collected by filtration and washed with a small amount of acetone and ether. The filtrate is con-centrated under reduced pressure and, on addition of acetone to the residue, a crystalline precipitate separates out, which is collected by filtration. The filtrate is concentrated and the residue treated in the same manner as above.
There is obtained 3.4 g in total of (3S,4R)-3-amino-4-cyano-2-azetidinone p-toluenesulfonate (A). The filtrate is concentrated under reduced pressure, ether added to the residue, and the insoluble matter collected by filtration and washed with ether to give 4.1 g of (3S,4S)-3-amino-4-cyano-2-azetidinone p-toluenesulfonate containing about 10% of (3S,4R)-isomer.
(A) IR i/KB r^-1 . j 7 7 0 ,12 0 0 NMR (DM SO -d6 , ppm) : 2.3 0 ( s , CH3 ) , 4. 5 5 ( d , J = 2Hz ,C4—H) , 4.9 5 ( d , J = 2Hz , C3 -H ) . 7.0 3 ( d , J = 8Hz , a r om H ) , 7. 4 6 ( d , J -• 8Hz , arom H ) ,8.30 ~9. 0 0 (broad.NH2) . 9. 4 6 (broad s ,NH) . w - & - 202907 (B) vtlr _ 1 IRv cm : 1800, 1180. max Example 14 1) To a mixture of 1.10 g of (3S,4RS)-4-cyano-3-tritylamino - 2 -azetidinone, 0.50 g of triethylamine and 20 ml of methylene chloride is added 0.56 g of tert-butyldimethylsilyl chloride under ice-cooling and stirring. The mixture is stirred at room temperature (approx. 25°C) for 30 minutes and the reaction mixture is concentrated under reduced pressure. The residue is chromatographed on a silicagel column [eluant: ethyl acetate-n-hexane (1:3)] to give 0.64 g of (3S,4RS)-1-tert-butyldimethylsilyl-4-cyano-3-tritylamino-2-azetidinone.
JR^max0"-1 = 2950,2240, 1760. 1260 NMR (CDC 13 , ppm ) : 0. 1 3 f s , CH3 ) , 0. 8 0 ( s , t-Bu), 3. 0 3 ( d , J =2Hz . C4 -H ) , 3. 1 0 ( d , J = 8Hz , NH ) . 8. 4 3 ( d , J = 5Hz . C4 -H ) . 4. 46 ( dd , J = 2 . 8Hz . C3-H ) . 4. 5 0 fdd , J = 5 , 8Hz , C3 -H ) , 7.00-7.50 (m, a r om H ) 2) A mixture of 0.4 69 g of the 4-cyano compound thus obtained in 1) above, 5 ml of methanol, 0.33 ml o 30% aqueous hydrogen peroxide and 1 ml of 1 N sodium ^ 5 JJJL1985' hydroxide is stirred at room temperature (approx. 25°C)1 for 4 hours. The reaction mixture is concentrated under reduced pressure and ethyl acetate and saturated aqueous sodium chloride are added to the residue. The organic layer is separated, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue is chromatographed on a silicagel column (eluant: ethyl acetate) to give 0.557 g of (3S,4RS)-4-carbamoyl-3-tritylamino-2-azetidinone ( 1:1 4R-4S mixture). 202907 1 7 5 0 ,1 6 7 0 NMR ( DMSO -de +D2O . ppm ) ; 3. 4 6 ( d , J = 4Hz , C4 -H ) , 8. 5 6 f d , J = 2Hz . C4 ~H ) . 4. 0 3 ( d . J = 2Hz . C3 -H ) . 4. 2 6 ( d , J = 4Hz . C3 -H ) , 7. 2 ~ 7. 7 ( m , a r om H ) 1) To a solution of 6 g of (3S,4S)-4-acetoxy-3-benzyloxycarboxamido-2-azetidinone in 30 ml of dimethylformamide is added a solution of 1.5 g of potassium cyanide in 5 ml of water under ice-cooling. The mixture is stirred at room temperature (approx. 25°C) for 30 minutes, poured into ice water and extracted with ethyl acetate. The ethyl acetate layer is washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue is dissolved in 30 ml of methylene chloride and, fol? addition of 2.2 g of triethylamine, 3.2 g of tert-buty^teilyl chloride is added under ice-cooling. The mixture is stirred at room temperature for 30 minutes and concentrated under reduced pressure. The residue is chromatographed on a silica gel column [eluant: ethyl acetate-n-hexane (1:1)] to give 0.300 g of (3S,4R)-3-benzyloxycarboxamido-l-tert-butyldimethylsilyl-4-cyano-2-azetidinone.
I R v 0,-1 : 2 9 5 0 . 2920, 2140, 1745, 1 7 2 0 ,1 2 5 0 NMR ( CDC13 , ppm ) : 0. 0 6 C s . CHg ) , 0. 9 0 ( s . t -Bu ) , 4. 8 6 ( d , J = 2Hz . C4 - H ) . 4.7 0 (dd ..] =2 . 8Hz . C3 Example 15 -H ) , 5 0 2 ( s , -CH2- ) , 5. 4 6 ( d , J = 8Hz , NH ) , 7.2 8 ( s , aromH ) - ^sr - 2 02907 2) In 5 ml of ethanol is dissolved 0.300 g of the 4-cyano compound thus obtained 1) above and, under ice-cooling, 0.3 ml of 30% aqueous hydrogen peroxide and 0.15 ml of 1 N sodium hydroxide are added. The mixture is stirred at room temperature (approx. 2 5°C) for an hour and concentrated under reduced pressure. The residue is shaken with ethyl acetate and water,and the ethyl acetate layer is separated, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue is chromatographed on a silica gel column [eluant: ethyl acetate] to give 0.04 g 1 5 2 0,1 2 5 0 NMR ( DMSO -de , ppm ) : 3. 9 1 ( d , J = 2Hz , C4 -H ) , 4.4 2 f dd , J = 2 . 8Hz , C3 -H ) . 5. 0 6 ( s , -CH2- ) , 7. 1 8 , 7. 6 0 (each br s , CONH2 ) , 7.3 6 f s , aromH), 8.0 4 ( d , J - 8Hz , NH ) . 8. 3 0 ( br s . NH ) In 1 ml of dimethyl sulfoxide is dissolved 122 mg of (3S,4S)-3-benzyloxycarboxamido-4-cyano-2-azetidinone and, under stirring at 20°C, 0.1 ml of 30% aqueous hydrogen peroxide and then 0.1 ml of 1 N sodium hydroxide are added. After 10 minutes, the crystalline precipitate is collected by filtration, washed with a small amount of 99% ethanol and dried to give 42 mg of (3S,4S)-3-benzyloxycarboxamido-4-carbamoyl-2-azetidinone. The filtrate is chromatographed on an xad-ii column (eluant: 30% aqueous ethanol) to give 37 mg of (3S,4S)-3-benzyloxycarboxamido-4-carbamoyl-2-azetidinone as a further crop. of (3S,4R)-3^benzyloxycarboxamido-4-carbamoyl-2-azetidinone. rap 153-155 cC (dec. ) = 1 7 7 0,1 7 0 5,1 6 9 0.1 6 6 5, Example 16 202907 mp 23 6~24 0 °C(dec. ) C a j20+ ! o. 4 8 ( DMSO , e -1 ) I R ^Jm"1 : 8 4 0 0 . 3 3 1 0 . : 8 4 0 0 , 3310. 1775. 1740 . 1 6 7 5 ,1 5 4 5 NMR ( DMSO , ppm ) : 4. 1 4 C d , J = 5Hz , C4 -H ) , 5.0 6 ( s . -CH2- ) . 5. 0 8 ( dd . J - 5 . 8Hz . C3 - H ) . 7. 3 0 (broad s , NH2 ). 7. 3 5 ( s , aromH) . 7. 5 2 ( d , J = 8Hz , NH ) , 8. 3 3 ( broad s . NH ) In 12 ml of dichloromethane is dissolved 1.06 g of (3S-4R,S)-4-cyano-3-triphenylmethylamino-2-azetidinone and, following addition of 1.02 g of tetra-n-butylammonium hydrogen sulfate, 0.68 ml of 30% aqueous hydrogen peroxide and 4.5 ml of 1 N sodium hydroxide are added under ice-cooling and stirring. The mixture is stirred vigorously for 50 minutes and poured into ice water containing 1.3 ml of 1 N hydrochloric acid. After phase separation, the aqueous layer is extracted twice with chloroform. The organic layers are combined and washed with an aqueous solution of sodium thiosulfate and sodium chloride, dried over magnesium sulfate, and concentrated under reduced pressure. The residue is chromatographed on a silica gel column [eluant: chloroform-ethyl acetate-methanol (50:50:5)] to give 0.223 g of (3S,4S)-4-carbamoyl-3-triphenylmethyl-amino-2-azetidinone.
I R r „-l :3370, 1750, 1675. 705 NMR ( DMSO -d6 . ppm ) : 3. 4 4 ( d , J = 5Hz , C4 -H ) , 3. 55 (d ,J = 10Hz,NH) , 4. 1 0 ( dd ,J=5,10Hz , Example 17 , 6. 9 0 (broad s .NH2) • 7. 0-7. 6 (m, a H ) , 7.8 9 ( s , NH) - $.
| NOW AMENDED 202507 Example 18 In 2 ml of dimethyl sulfoxide is dissolved 0.38 g of (3S,4S)-3-[2-(2-chloroacetamidothiazol-4-yl)yl-(1-p-nitrobenzyloxycarbonyl-l-methylethoxyimino) aceftamido] -4-cyano-2-azetidinone and, following addition,of 0.1 ml of 30% aqueous hydrogen peroxide and 0.1 ml/of 1 N sodium hydroxide, the mixture is stirred at a-^prox. 25°C for 30 minutes. The reaction mixture is chromatographed on an XAD-II column (eluant: 30% ethanol) to give 0.12 g of (3S,4S)-4-carbamoyl-3-[2-(2-ch^oroacetamidothiazol-4-yl)-2-(1-p-nitrobenzyloxycarbonyi-l-methylethoxyimino)acetamido] 2-azetidinone.
IRf KBr^-i . max" :1 7/6 0,1750,1680,1520,1350 NMR ( DMSO -/s • PPm > : 1. 5 2 ( s , CH3 ) , 4. 2 7 C d 6Hz , C4/-U ) , 4.3 4 ( s , C) CH2-),5,32(s H2-), . 4 ji/f'dd , J = 6 . 9Hz , C3 -H ) , 7. 4 1 ( ) / 7. 60 , 8. 08 ( £ * d , J = 9Hz , aromH 8. 4 7 ( s , NH), 8. 8 6 ( d , J = 9Hz , NH ) Example In 2 ml of dichloromethane is dissolved 160 mg of (3S,4S)-4-cyano-3-triphenylmethylamino-2-azetidinone and, following addition of134 mg of tetra-n-butylammonium hydrogen sulfate, 0.103 ml of 30% aqueous hydrogen peroxide and 0.68 ml of 1 N sodium hydroxide are added under ice-cooling and stirring. The mixture is stirred vigorously for 30 minutes and poured into ice water containing 0.22 ml of 1 N hydrochloric acid. After phase separation, the aqueous layer is extracted twice with chloroform. The organic layers are combined, washed with aqueous sodium chloride, dried over magnesium sulfate and cojxg®e£,rated under reduced pressure. The residue is cl^^^tog'r^^ed on 2 15JUU985; £ j \< AS AMENDED Example 18 In 2 ml of dimethyl sulfoxide is dissolved 0.38 g of (3S,4S)-3-[2-(2-chloroacetamidothiazol-4-yl)-2-(1-p-nitrobenzyloxycarbonyl-l-methylethoxyimino)acetamido]-4-cyano-2-azetidinone and, following addition of 0.1 ml of 30% aqueous hydrogen peroxide and 0.1 ml of 1 N sodium hydroxide, the mixture is stirred at approx. 2 5°C for 30 minutes. The reaction mixture is chromatographed on an XAD-II column (eluant: 30% ethanol) to give 0.12 g of (3S,4S)-4-carbamoyl-3-[2-(2-chloroacetamidothiazol-4-yl)-2-(1-p-nitrobenzyloxycarbonyl-l-methylethoxyimino)acetamido] 2-azetidinone.
NMR ( DMSO-dg , ppm ) : l. 5 2 ( s . CH3 ) , 4. 2 7 ( d , J = 6Hz , C4-H ) , 4.3 4 ( s , CI CH2 - ) ,5.3 2 ( s, -CH2-) 5. 4 6 ( dd , J = 6 . 9Hz , C3-H ) , 7. 4 1 C s . S>~H ) 7. 6 0 , 8. 0 8 (each d , J = 9Hz , a r om H ) , 8. 4 7 ( s . NH), In 2 ml of dichloromethane is dissolved 160 mg of (3S,4S)-4-cyano-3-triphenylmethylamino-2-azetidinone and, following addition of 154 mg of tetra-n-butylammonium hydrogen sulfate, 0.103 ml of 30% aqueous hydrogen peroxide and 0.68 ml of 1 N sodium hydroxide are added under ice-cooling and stirring. The mixture is stirred vigorously for 3 0 minutes and poured into ice water containing 0.22 ml of 1 N hydrochloric acid. After phase separation, the aqueous layer is extracted twice with chloroform. The organic layers are combined, washed with aqueous sodium chloride, dried over magnesium sulfate and concentrated under reduced pressure. The residue is chromatographed on ^"max011'-1760 .1750 ,1680 .1520 ,1350 C 1985^1 8. 86 (d , J = 9Hz , NH ) Example 19 202907 a silica gel column [eluant: chloroform-ethyl acetate-methanol (50:50:5)] to give 75 mg of (3S,4S)-4-carbamoyl-3-triphenylmethylamino-2-azetidinone. The IR and NMR spectra of this compound are identical with those of the compound obtained in Example 17.
Example 2 0 In 120 ml of carbon tetrachloride are dissolved 12.2 g of (3R,4R)-4-methylsulfonyl-3-tritylamino-2-azetidinone and 2.44 g of tri-n-octylmethylammonium chloride and, under stirring, a solution of 2.15 g of potassium cyanide in 30 ml of water is added. The mixture is stirred vigorously at the same temperature for 15 minutes and the organic layer is separated, while the aqueous layer is extracted with chloroform. The organic layers are combined, washed with water and treated in the same manner as 1) of Example 13 to give 7.66 g of (3S,4RS)-4-cyano-3-tritylamino-2-azetidinone.
This compound is a 1:1 mixture of (3S/4R) and (3S,4S) forms.
° ( S S , 4 R ) compound NMR ( CDC la . PPm ) = 2. 9 4 ( d , J - 1 lHz . Tr (trityl ) NH-) . 8. 0 0 ( d , J - 2Hz . C4-H) , 4.6 4 ( dd , J - 2 . 1 lHz . C8—H ) , 6. 4 0 ( s , Nil) . 7.1—7.7 (m , aromH) ° ( 3 S , 4 S ) compound NMR(CDC13 . ppm) ; 3. 1 7 ( d , J - i l Hz , Tr NH - ) , 3. 5 6 ( d , J = 5Hz , C4 -H ) , 4. 6 4 ( dd , J = 5 . 1 1 Hz . C3 -H ) . 6. 3 0 ( s , NH ) , 7.1.-7.7 (m . a r om H ) 5V - y* - 2029OT Example 21 In 40 ml of chloroform is dissolved 3.54 g of (3S.,4RS)-4-cyano-3-tritylamino-2-azetidinone as obtained in Example 20 and, following addition of 3.4 g of tetra-n-butylammonium hydrogen sulfate, 2.3 g of 30% hydrogen peroxide and 15 ml of 1 N sodium hydroxide are added under ice-cooling and stirring. The mixture is stirred vigorously for 30 minutes and the organic layer is taken out, while the aqueous layer is extracted twice with chloroform. The organic layers are combined, washed with water and treated in the same manner as Example 19 to give 0.76 g of (3S,4S)-4-carbamoyl-3-trityl-amino-2-azetidinone. The IR and NrfK spectra of this compound are identical with those of the compound obtained in Example 17.
In 2 ml of benzene are dissolved 0.5 mmol of (3R,4R)-4-methylsulfonyl-3-tritylamino-2-azetidinone and 0.1 mmol of tetra-n-amylammonium bromide, and a solution of 0.55 mmol of potassium cyanide in 0.55 ml of water is added at 15CC. The mixture is stirred vigorously for 15 minutes and treated in the same manner as Example 20 to give (3S,4RS)-4-cyano-3-tritylamino-2-azetidinone with the (3S ,4R) : (3S,4£) ratio of 1:4.
Using benzyltriethylammonium chloride instead of tetra-n-amylammonium bromide, the procedure of Example 22 is repeated to give (3£,4RS)-4-cyano-3-tritylamino-2-azetidinone (4R:4S = 1:3.5).
Using tetra-n-butylphosphonium instead of tetra-n-amylammonium bromide, the procedure of Example 22 is repeated to give (3S,4RS)-4-cyano-3-tritylamino-2-azetidinone (4R:4S = 1:3.5).
Example 22 Example 23 Example 24 202907 <5* -yi-- Reference Example (1) In 2 ml of dry N,N-dimethyIformamide is dissovled 630 mg of (3S,4S)-4-carbamoyl-3-[2-(2-chloroacetamido- thiazol-4-yl)-2-(1-p-nitrobenzyloxycarbonyl-l-methylethoxy imino) acetamido]-2-azetidinone (syn-isomer) as obtained ii.
Example 18. Then, at -78°C, 1.69 ml of sulfuric anhydride-l\!. N-dimethyIformamide complex solution (1.56 M) is added.
The mixture is allowed to stand at 4°C in a refrigerator overnight. To this reaction mixture are added 208 mg of pyridine under ice-cooling and then 30 ml of ether, and the resultant syrupy precipitate is washed with ether by the decantation method (20 ml x 3). The precipitate is dissolved in 15 ml of water, and after addition of 15 ml of Dowex 5 0W (Na-form) resin, the mixture is strirred at room temperature for 2 hours. The resin is filtered off and the filtrate is concentrated under reduced pressure. The residue is chromatographed on an Amberlite XAD-II column and serial elution is carried out with water and 10-20% ethanol to give the 1,4-disulfo compound, followed by further elution with 40% ethanol. The fraction of 40% ethanol including desired compound is lyophilized to give 480 mg of sodium (3S,4S)i-4-carbamoyl-3-[2-(2-chloroacetamidothiazol-4-yl)-2-(1-p-nitrobenzyloxycarbonyl-l-methylethoxyimino)acetamido] -2-azetidinone-l-sulfonate (syn-isomer). (2) In 20 ml of water is dissolved 480 mg of sodium (3S,4S)~ 4-carbamoyl-3-[2- (2-chloroacetamidothiazol-4-yl) -2- (1-p- ^^===5^^ nitrobenzyloxycarbonyl-l-methylethoxyimino) acetamido] azetidinone-l-sulfonate (syn-isomer) as obtained in the/hf j[z 4 above (1) and under ice-cooling and strirring, 104 mg of l5JULI985n-sodium monomethyldithiocarbamate is added. The mixtureVfc / c I stirred at room temperature for 1.5 hours. The reaction mixture is twice washed with ether, and then purified by column chromatography on Amberlite XAD-II (40 g), eluting with water and then 20% ethanol. The fractions including the desired product are combined and lyophilized to give 300 mg of sodium (3S,4S)-4-carbamoyl-3-[2-(2-aminothiazol-4-yl)-2-(1-nitrobenzyloxycarbonyl-l-methylethoxyimino)acetamidoj , , 202507 - ** " -2-azetidinone-l-sulfonate (syn-isomer). (3) In 10 ml of water is dissolved 300 mg of sodium (3S,4S)-4-carbamoyl-3-[2-(2-aminothiazol-4-yl)-2-(1-p-nitrobenzyloxycarbonyl-l-methylethoxyimino)acetamido]-2-azetidinone-l-sulfonate (.syn-isomer) as obtained in the above (2), followed by addition of 300 mg of 10% palladium-on-carbon. The mixture is stirred in a hydrogen atmosphere at room temperature for one hour. The catalyst is filtered off, and under ice-cooling 27 mg of sodium hydrogen carbonate is added. The mixture is stirred for 5 minutes and washed with ethyl acetate. To the aqueous layer is added 30 ml of Dowex 50W (H-form) resin, and the mixture is stirred for 1.5 hours. The resin is filtered off and the filtrate is concentrated under reduced pressure to about a half volume thereof. The residue is chromatographed on an Amberlite XAD-II (4 0 g) column, eluting with water and then 15% ethanol. The fractions including the desired product are combined arid lyophilized to give 150 mg of (3S,4S)-4-carbamoyl-3-[2-(2-aminothiazol-4-yl)-2-(1-methyl-l-carboxyethoxyimino)acetamido]-2-azetidinone-l-sulfonic acid (syn-isomer). r„i 23 D -37.8° (C=1.01, H-O) 1 Anal. Calcd. for C^3H^gNgOgS2 '2 H2®: C , 3 0. 6 5; H, 4.15; N,16.50 Found: C,30.74; H, 4.27; N,16.55 IR vKBr -1 : 3340, 1770, 1720, 1680, 1635, 1275, 1050 max cm NMR (dg-DMSO, ppm): 1.52 (6H, S, 2 x CH3), 4.78 (1H, d, J=6Hz, C4-H), 5.33 (1H, d,d, J=6, 9Hz, C3~H), 7,20 (1H, S, SXH), 7.29 - 7.59 (2H, CONH2), 9.19 (1H, d, J=9Hz, C3-NH).

Claims (11)

  1. f
  2. Z029O7[
  3. Industrial Utility
  4. 4-Cyano-2-azetidinone derivatives [I] are useful as advantageous intermediates in the synthesis of optically active 4-substituted-2-azetidinone derivatives having excellent antimicrobial and beta-lactamase inhibiting activities. When W is a sulfo group, [I] per se have antimicrobial and beta-lactamase inhibiting activities and are useful as therapeutic agents for treating infectious diseases caused by gram-positive or negative bacteria in humans and mammals including dogs, cats, cattle, horses, mice and guinea pigs, as preservatives for animal feed and industrial water, or as disinfectants for sanitary tools and appliances, and further as degradation inhibitors for beta-lactam antibiotics in combined use thereof with said antibiotics. St - ps - 202907 What we claim is: A 4-cyano-2-azetidinone derivative of the formula R1 X CN wherein R* is an amino group optionally acylated or protected, X is a hydrogen atom or a roethoxy group and W is a hydrogen atom or a sulfo group, or a salt or an ester thereof- 2. A compound as claimed in Claim 1, wherein W is a hydrogen atom. 3. A compound as claimed in Claim 1, wherein the protective group of the protected amino group is an easily removable protective group commonly used for protecting an amino group in the field of beta-lactam chemistry and peptide synthesis. 4. A compound as claimed in Claim 3, wherein the protective group is .an aromatic acyl, aliphatic acyl or amino-protecting group other than an acyl group.
  5. 5. A compound as claimed in Claim 1, wherein the acyl moiety of the acylated amino group is a group of the formula: R5-CO- wherein R"* is a lower alkyl, phenyl* or a heterocyclic group*; a group of the formula: R6-NH-CH-CO-R7 wherein R is hydrogen, an amino acid residue*, an amino- 8 8 protective group or a group R where R is an amino, heterocyclic group*, phenyl* or alkyl* and n. is an 7 integer of 0 to 3, and R is a lower alkyl*, phenyl*, heterocyclic* or cycloalkenyl* group; a group of the formula: r9-r10-co- wherein R^ is a group R^-^- where R^ is a heterocyclic
  6. 6-R- 2 202307 if - M - 12 group* or phenyl* and R is hydrogen, phenyl*, C2~4 acyl or a lower alkyl or a group -R^-R^ where R^ is a C 14 alkylene or C2-3 alkenylene and R is carboxyl or an ester thereof, and R^ is a direct bond or a group -CO-NH-CH-15 'it (where R is a lower alkyl or thiazolyl*); R a group of the formula: wherein R*^ is hydroxy, carboxyl, sulfo, formyloxy, halogen or azido and R^ is hydrogen, a lower alkyl, a C1-6 alkoxy, halogen or hydroxy; or a group of the formula: IP i q R -R -CH„—CO- 18 wherein R is cyano, phenyl*, phenoxy*, a lower alkyl*, 19 alkenyl* or a heterocyclic group* and R is a direct bond or -S-, wherein the groupswith a superscript asterisk "*" may be substituted with one to four substituents which and may be the same or different,/the amino, carboxyl and hydroxy1 group^may be protected. 6. A compound as claimed in Claim 1, wherein the acyl moiety of the acylated amino group is a group of the formula: R8'-CONH-CH-CO- k1' •j i g i each wherein R and R are/a heterocyclic group which may be substituted, or a group of the formula: 111 R -C-CO-I N 4 12' O-R 11' wherein R is a heterocyclic group which may be substituted, 12' and R is a lower alkyl group. any one of
  7. 7. A compound as claimed ir/Claims 1-6, wherein the cyano group has cis configuration to the group R^" having B-configuration to the azetidine ring. vV ;{N V- «<■ 5b - -frs"- 202907
  8. 8. A compound as claimed in Claim 1, which is 4-cyano-3-tritylamino-2-azetidinone.
  9. 9. A method of producing a 4-cyano-2-azetidinone derivative of the formula .. R X CN £ < W wherein R^" is an amino group optionally acylated or protected, X is a hydrogen atom or a roethoxy group and W is a hydrogen atom or a sulfo group, or a salt or ester thereof, which comprises (1) reacting a compound of the formula 2 wherein R is an acylated or protected amino group, X is as defined above and Y is a halogen atom or a aroup represented by the formula o S -O-C-R / -O-C-r or —S(O) -r^ (r^ being a hydrocarbyl group and n an integer 1 or 2), or a salt, ester or silyl derivative thereof, with a cyano compound, (2) reacting a compound of the formula "ch H2N\yX P1 M>R\985mJ f f U r<* N vw wherein X and W are as defined above, or a salt, ester or silyl derivative thereof, with a carboxylic acid of the formula R°COOH ^ wherein R^CO is an acyl group, or a functional derivative thereof, or (3) sulfonating a compound of the formula i Ryx /CN 0J—HH wherein R^" and X are as defined above, or a salt, ester or silyl derivative group. thereof,and, if necessary, eliminating the protective G1 - - 202907
  10. 10. A method according to Claim 9, wherein the reaction of the process (1) is carried out in the presence of a phase transfer catalyst.
  11. 11. A method of producing a 4-carbamoyl-2-azetidinone derivative of the formula ,4 LUWti^ III wherein R is an amino group optionally acylated or protected and X is a hydrogen atom or a methoxy group, or a salt or ester thereof, which comprises hydrating a compound of the formula wherein R is an amino group optionally acylated or protected, X is as defined above, or a salt, ester or silyl derivative thereof, and, if necessary, eliminating the protective group. as claimed in Claim 1 12. A compound of formula [I]/substantially as specifically described herein in any one of the Examples. , . , . , J * as claimed m Claim 1 as '°iri ?^uc^-n9 a compound of formula [I]/or [III]/ substantially as specifically described herein in any one of the Examples. NEYS FOR TtfE APPLICANTS ni: 3 0APRi985,:;j _ /
NZ202907A 1982-04-27 1982-12-23 4-cyano-2-azetidinone derivatives;pharmaceutical compositions containing them and their use in preparing 4-carbamoyl-2-azetidinones NZ202907A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1982/000141 WO1983003827A1 (en) 1982-04-27 1982-04-27 4-cyano-2-azetidinone derivatives and process for their preparation

Publications (1)

Publication Number Publication Date
NZ202907A true NZ202907A (en) 1986-01-24

Family

ID=13762237

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ202907A NZ202907A (en) 1982-04-27 1982-12-23 4-cyano-2-azetidinone derivatives;pharmaceutical compositions containing them and their use in preparing 4-carbamoyl-2-azetidinones

Country Status (3)

Country Link
JP (1) JPS591465A (en)
NZ (1) NZ202907A (en)
WO (1) WO1983003827A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA826089B (en) * 1981-08-27 1983-07-27 Hoffmann La Roche Beta-lactams

Also Published As

Publication number Publication date
JPH0425264B2 (en) 1992-04-30
WO1983003827A1 (en) 1983-11-10
JPS591465A (en) 1984-01-06

Similar Documents

Publication Publication Date Title
US4794108A (en) 1-carboxymethoxy acetidinones and their production
JPH0333154B2 (en)
JPH0357108B2 (en)
US4816582A (en) Antimicrobial 2-oxo-1-azetidinesulphonic acids
EP0093376B2 (en) 1-Sulfo-2-azetidinone derivatives, their production and use
NZ199168A (en) 2-oxoazetidine derivatives and pharmaceutical compositions
EP0083039B1 (en) 4-cyano-2-azetidinones and production thereof
US4195021A (en) 1,3-Disubstituted 2-azetidinone antibitotics
US4647558A (en) Antibacterial agents, their preparation and use
NZ202907A (en) 4-cyano-2-azetidinone derivatives;pharmaceutical compositions containing them and their use in preparing 4-carbamoyl-2-azetidinones
US4533495A (en) Method of producing 2-azetidinone-1-sulfonic acid compounds
US4416817A (en) 3-Methoxy-2-oxoazetidine derivatives and their production
JPS642118B2 (en)
IE54682B1 (en) 4-cyano-2-azetidinones and production thereof
JP2936404B2 (en) Method for producing penam-3-carboxylic acid derivative and penam-2,3-dicarboxylic acid derivative
US5821362A (en) Method of desilylating silylether compounds
EP0100041B1 (en) 1-sulfo-2-azetidinone derivatives, their production and use
KR100253783B1 (en) Cephalosporin pyridinium derivatives
KR890000226B1 (en) Process for preparing 1-sulfo-2-oxoazetidine derivatives
KR880000874B1 (en) Process for preparing 1-sulfo-2-oxo azetidine derivatives
JPS63107977A (en) Isoxazolone derivative
KR930001405B1 (en) Process for preparing 2-(4-substituted amino-3-oxo-isoxazolydin-5-oxo)-tetra hydrofuran carboxyl acid derivatives
JPS642117B2 (en)
JP2006096679A (en) Manufacturing method of cephalosporin compound
JPH05331175A (en) New cephalosporin derivative and salt thereof